PROCEDURE FOR SYRINGE STERILIZATION

DE502022001968D1Active Publication Date: 2024-11-14FARCO PHARMA GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE502022001968
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-05-07
Filing Date
2022-02-21
Publication Date
2024-11-14
Estimated Expiration
2042-02-21

AI Technical Summary

Technical Problem

Current methods for sterilizing oxybutynin-containing compositions in piston syringes face challenges such as instability and degradation of the active ingredient during sterilization, leading to reduced active ingredient content and formation of undesirable degradation products, particularly with polypropylene-based syringes, which affects the efficacy and safety of the composition.

Method used

A method for producing a sterile oxybutynin-containing composition using polypropylene-based piston syringes involves controlling the migration and degradation of oxybutynin through adjusting the concentration, pH, and sterilization conditions, including steam sterilization, and using migration-reducing agents like silicone coatings to maintain the active ingredient's stability and concentration.

Benefits of technology

This approach ensures a sterile, ready-to-use oxybutynin composition with a high and unchanged active ingredient content, reduced degradation products, and improved storage stability, while being cost-effective and scalable for industrial use.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to the medical-technical field of sterilization or germ reduction of a special composition which contains oxybutynin or oxybutynin hydrochloride as the active ingredient and which is introduced into or is present in a particularly ready-to-use piston syringe.

[0002] In particular, the present invention relates to a process for producing a sterile oxybutyn-containing composition in a preferably ready-to-use piston syringe or for producing a preferably ready-to-use, sterile piston syringe filled with an oxybutyn-containing composition.

[0003] Also described herein, but not claimed, is a sterile oxybutynin-containing composition as such, as is used in particular for the prophylactic or therapeutic treatment of neurogenic bladder dysfunction, in particular by instillation into the urinary bladder.

[0004] Furthermore, a piston syringe filled with the sterile oxbutynin-containing composition as such is also described herein, wherein the oxybutynin-containing composition contained in the piston syringe, including the piston syringe, has been steam sterilized according to the method according to the invention.

[0005] Also described, but not claimed, is a packaging unit which has at least one piston syringe according to the invention, wherein the piston syringe is introduced into a packaging or is present in a packaging.

[0006] Also described, but not claimed, are corresponding kits based on the piston syringe according to the invention or the oxybutyn-containing composition according to the invention.

[0007] Also described, but not claimed, is the use of a piston syringe in a process for producing a sterile oxybutyn-containing composition and also the use of heat sterilization in a process for producing a sterile oxybutyn-containing composition in a preferably ready-to-use piston syringe.

[0008] The active ingredient oxybutynin (synonymously known as 4-diethylaminobut-2-ynyl-2-cyclohexyl-2-hydroxy-2-phenylethanoate) or oxybutynin hydrochloride is an anticholinergic used to treat bladder dysfunctions or dysfunctions of the urinary bladder, particularly those bladder dysfunctions that are accompanied by or caused by detrusor overactivity and / or detrusor-sphincter dyssynergia.

[0009] Neurogenic bladder dysfunction (nBFS) or neurogenic bladder emptying disorders represent a pathological condition of the bladder and the anatomical structures involved in urine storage and excretion that often requires treatment. Neurogenic bladder dysfunctions primarily involve dysfunctions of the bladder or the relevant anatomical structures that occur as a result of a malfunction or injury to the nervous system, for example, as a result of spinal cord injuries, spina bifida ("open back"), diabetes, multiple sclerosis, stroke, or Parkinson's disease. The suffering associated with bladder dysfunction for patients is sometimes very severe, especially since the symptoms associated with the dysfunction further worsen the already limited quality of life.

[0010] In general, neurogenic bladder dysfunction (nBFS) is defined as a disorder of urine storage or urination, which is caused primarily by neurological changes or injuries in the spinal cord, in the parts of the brain relevant to bladder function, or in the periphery, whereby normal neural signal transmission for controlling the urinary bladder is often impaired or hindered. As a result of the underlying neurological damage, the natural function of the urinary bladder is disrupted with regard to its functional states, namely a (urinary) filling phase on the one hand and a (urinary) emptying or micturition phase on the other. The physiological process of bladder filling and emptying can even be impaired or prevented on several levels.

[0011] As a result of neurological dysfunction, neurogenic bladder dysfunction (nBFS) is often characterized by detrusor overactivity and / or detrusor-sphincter dyssynergia. This is frequently accompanied by a disruption in the interaction or coordination of the anatomical structures relevant to natural bladder function.

[0012] The detrusor (Musculus detrusor vesicaeThe detrusor muscle (also known as the "detrusor muscle") is a powerful muscle system that surrounds or forms part of the urinary bladder. The detrusor muscle is a smooth muscle that, in a physiological situation, plays a major role in micturition or bladder emptying, and thus in the expulsion of urine. Signals from the parasympathetic nervous system cause the muscle system to contract, thereby placing pressure on the bladder contents. The detrusor muscle is also influenced by an intrinsic nerve plexus located in the bladder wall, which adjusts its tone to the bladder's fullness.

[0013] In the pathological situation, neurogenic bladder dysfunction is often accompanied by detrusor hyperactivity, which in this context is also referred to as neurogenic detrusor hyperactivity ( N eurogenic Detrusor Overactifity, NDO)Detrusor hyperactivity associated with a relevant underlying neurological disorder is particularly associated with pollakiuria, nocturia, and excessive urge symptoms.

[0014] In detrusor-sphincter dyssynergia (DSD), the interaction of the anatomical structures involved in bladder emptying is also disrupted. Detrusor overactivity is juxtaposed with spastic dysfunction of the pelvic floor muscles or the external bladder sphincter, leading to obstruction of the bladder outlet with simultaneous urination effort. Typical symptoms of detrusor-sphincter dyssynergia include a frequently interrupted urine stream and difficulty initiating urination. Pollakiuria and residual urine formation are also often present.

[0015] In addition to the aforementioned symptoms, neurogenic bladder dysfunction is often associated with high intravesical pressures, i.e., excessive pressure builds up in the bladder due to detrusor hyperactivity or detrusor-sphincter dyssynergia. This also poses a risk to the upper urinary tract, as excessively high intravesical pressures are often associated with or even cause kidney damage.

[0016] In light of the above, there is a great need in the state of the art to provide therapeutic concepts that lead to a normalization or improvement of bladder function or a reduction of symptoms in the presence of neurogenic bladder dysfunction, both with regard to urinary difficulties and the existing high pressures in the bladder. In addition to improving urination, a key goal is also to reduce intrinsic pressure in order to prevent possible kidney damage or similar.

[0017] In this context, the treatment of neurogenic bladder dysfunction pursues several goals, namely the protection of the upper urinary tract and kidney function, the improvement of continence, the restoration or improvement of the function of the lower urinary tract and, last but not least, the improvement of quality of life.

[0018] In addition to conservative measures such as regular exercise, targeted bladder training, or similar, pharmacotherapeutic measures are also used to treat neurogenic bladder dysfunction. For example, an injection of botulinum toxin into the bladder wall can be performed using minimally invasive procedures to reduce detrusor activity. However, administration is relatively complex and can only be performed by a physician, as the active substance must be injected into the bladder wall, which is a relatively laborious process. Furthermore, minimally invasive procedures such as sacral neuromodulation are also used. In this case, a pacemaker is implanted in the upper buttocks area, which delivers weak electrical impulses to the sacral nerves via an electrode. However, its application is limited due to the underlying diseases.In addition, this is a significant surgical procedure that involves additional risks.

[0019] In addition, pharmacological therapies involving anticholinergics are known in the prior art. In this context, particular emphasis is placed on the administration of oxybutynin or oxybutynin hydrochloride, trospium chloride, propiverine, tolterodine, or similar drugs. The prior art focuses on the systemic or oral application or administration of these active substances. However, systemic administration can be associated with increased systemic side effects, such as residual urine formation, constipation, accommodation disorders, dry mouth, tachycardia, cardiac arrhythmias, and the like. Furthermore, the concentration of the active substance at the site of action, namely the bladder, is sometimes not optimally adjustable.

[0020] Furthermore, systemic administration of the active substance in the form of anticholinergics is disadvantageous in that part of the administered active substance is metabolised during its first passage in the gastrointestinal tract or in the liver (so-called First Pass metabolism), which sometimes results in inactive metabolites, resulting in lower bioavailability at the site of action or difficulty in adjusting or specifying the effective dose at the site of action. Consequently, patients may not be adequately controlled with systemic dosage forms.

[0021] EP 1 088 565 A1 relates to a sealed package with a set for intravesical instillation, comprising a sterilized disposable syringe with an opaque barrel and a latex-free sealing ring at the front end of the plunger, filled with an isotonic sodium chloride solution of a pharmaceutical active ingredient, a sterilized adapter and a sterilized closure cap.

[0022] DE 10 2017 104 931 A1 relates to a method for, in particular, thermal sterilization of a syringe, wherein the syringe is suitable for receiving or dispensing at least one medical filling material. The syringe body has a receiving space for receiving the filling material, wherein the receiving space can be sealed via an opening with at least one detachable or displaceable sealing device. The sealing device has a first sealing lamella in contact with the wall of the syringe, facing the receiving space or remote from the opening, and at least one second sealing lamella in contact with the wall, facing away from the receiving space or remote from the opening, wherein the first sealing lamella and the second sealing lamella delimit an intermediate space.The second sealing lamella should be provided with at least one recess, in particular such that a sterilization atmosphere is able to penetrate through the recess into the space delimited by the two sealing lamellas.

[0023] EP 3 888 630 A1 relates to a process for producing a sterile oxybutyn-containing composition in a preferably ready-to-use plunger syringe. The syringe body is said to be made of a cycloolefin (co)polymer (COP or COC).

[0024] WO 2012 / 154779 A1 and US 2012 / 0289564 A1, which belongs to the same patent family, relate to the use of a combination of oxybutynin and a saliva-stimulating substance for the treatment of overactive bladder, with a focus on oral administration.

[0025] In addition, anticholinergics can be applied topically, for example, via a transdermal patch or similar. Even with this systemic application, systemic side effects can occur to a greater extent. Furthermore, there is also the problem of premature metabolism.

[0026] In addition, anticholinergics such as oxybutynin or oxybutynin hydrochloride can be applied or instilled topically into the urogenital area, particularly the bladder, for example, via a catheter or similar device. Through this local application or instillation, the active substance is delivered directly to its site of action, thereby increasing the targeted effect and bioavailability and reducing systemic side effects. Furthermore, with this method of administration, the active ingredient is not prematurely metabolized via other organs. Furthermore, this administration can also be carried out by the patient themselves, if necessary.

[0027] Oxybutynin or oxybutynin hydrochloride acts primarily as a competitive antagonist of acetylcholine on postganglionic muscarinic receptors, leading to a relaxing or antispasmodic effect on the smooth bladder muscle and thus also to a reduction in detrusor overactivity. In particular, bladder contractions are inhibited, whereby spasms are also eased. In addition, the administration of oxybutynin or oxybutynin hydrochloride leads to an increase in bladder volume and a reduction in contractions, whereby the urge to urinate is also reduced or delayed in neurogenic bladder dysfunction. Furthermore, the use of oxybutynin or oxybutynin hydrochloride can also reduce intravesical (bladder) pressure, which also leads to relief of the upper urinary tract. In addition, oxybutynin or oxybutynin hydrochloride exhibits the properties of a local anesthetic.Oxybutynin hydrochloride belongs in particular to the group of parasympatholytics.

[0028] In the context of the instillation or topical application into the urinary bladder provided for in the prior art, oxybutynin or oxybutynin hydrochloride is generally used in the form of an aqueous composition (aqueous formulations) or aqueous solution, wherein the active ingredient-containing composition or solution is applied or administered into the urinary bladder using appropriate application devices.

[0029] The sterility of a composition used for instillation or topical administration into the bladder is of great importance, particularly in order to avoid possible infections of the bladder, which is particularly susceptible to this and may already be damaged by the disease.

[0030] In order to avoid contamination, the active ingredient-containing compositions can, for example, be prepared immediately before their use or administration. However, this is complex and also involves a certain risk of contamination of the composition during production. Furthermore, the active ingredient-containing compositions can be sterilized as such, for example by means of microfiltration processes or the like, and then filled into a storage or application device. However, this can also lead to undesirable contamination, particularly with regard to possible germs or the like adhering to the storage or application device. In this context, separate sterilization of the storage or application device can also be advantageous.An application device may be provided, but this can also lead to unsatisfactory sterilization results, particularly due to the subsequent filling of the composition into the receiving or application device. In this context, it is also possible to work under sterile conditions, for example, under clean room conditions, but this involves a certain amount of effort and is also costly.

[0031] Another problem with sterilization is that the active ingredient content in the underlying aqueous composition or aqueous formulation cannot always be maintained. It has also been assumed that degradation of the active substance in the form of oxybutynin or oxybutynin hydrochloride occurs, accompanied by the formation of undesirable degradation products, for example as a result of undesirable interaction of the active substance with materials that are in direct contact with the underlying aqueous composition, such as materials of corresponding storage or application devices or the like. Reducing the amount of active ingredient in an underlying composition orHowever, the formation of undesirable degradation products can negatively influence the efficacy and safety of a corresponding composition, so that it can sometimes no longer be used after sterilization, which also entails a corresponding economic loss.

[0032] In this context, it has so far been assumed in particular that there is an incompatibility or instability for oxybutynin or oxybutynin hydrochloride in aqueous compositions, particularly during thermal sterilization, and in particular in the case that the aqueous compositions with the oxybutynin or oxybutynin hydrochloride are present in (disposable) syringes based on polypropylene (PP) as the syringe material, wherein it has also been assumed that the incompatibility or instability is sometimes further increased by the fact that piston stoppers or rubber stoppers and closure caps made of commonly used rubber materials are generally used for the syringe.

[0033] In such systems, a sometimes significant reduction in the amount of active ingredient in the form of oxybutynin or oxybutynin hydrochloride has been found to date, particularly during (steam) sterilization, so that it has been assumed to date that such (disposable) syringes based on polypropylene, particularly in combination with the use of piston stoppers or rubber stoppers and closure caps made of commonly used rubber materials, are not suitable for corresponding aqueous compositions containing oxybutynin or oxybutynin hydrochloride as the active ingredient.With regard to the use of (disposable) syringes with the corresponding syringe barrel and piston rod made of polypropylene as primary packaging for corresponding aqueous compositions, it has thus far been assumed that an aqueous composition incorporated therein using oxybutynin or oxybutynin hydrochloride as the active ingredient is not stable, particularly during sterilization, whereby a degradation of the active ingredient in the form of oxybutynin or oxybutynin hydrochloride, particularly into its hydrolysis product, has been assumed, accompanied by a corresponding reduction in the amount or concentration of the active ingredient in the composition.

[0034] Against this background, the prior art, for example, pursues a concept whereby (disposable) syringes based on other materials are used as primary packaging or for the storage and sterilization of aqueous compositions containing oxybutynin or oxybutynin hydrochloride, such as syringes made of cycloolefin (co)polymer (COP or COC). By using corresponding (disposable) syringes based on COP or COC, which are also designed in particular as piston syringes, the composition is intended to be stabilized with regard to the active ingredient in the form of oxybutynin or oxybutynin hydrochloride, particularly during sterilization, in such a way that any loss of active ingredient in the composition is reduced, in order to provide sterile and ready-to-use compositions with a constant or, as far as possible, unchanged active ingredient content and with improved product and storage properties.However, corresponding (disposable) syringes made of COP or COC are sometimes relatively scratch-sensitive and, particularly due to the relatively high rigidity of the material, are somewhat fragile and more sensitive to mechanical influences and to strong temperature fluctuations, which sometimes affects their handling, even during (heat) sterilization. Furthermore, (disposable) syringes made of COP or COC are relatively expensive and therefore less economical.

[0035] Overall, (disposable) syringes made of COP or COC are such a primary packaging material for an aqueous composition with oxybutynin or oxybutynin hydrochloride as the active ingredient, which generally ensures a high (storage) stability of the compositions absorbed and sterilized therein, but is overall cost-intensive and sometimes also entails increased requirements with regard to the implementation of (heat) sterilization.

[0036] Overall, there is therefore a great need in the state of the art for corresponding concepts that enable the effective sterilization of aqueous compositions containing oxybutynin or oxybutynin hydrochloride as the active ingredient present in corresponding receiving or application devices, while maintaining the stability of the compositions. This allows for the development of ready-to-use products that are highly effective and safe for instillation into the bladder (i.e., do not lead to infections or misuse during use despite a high active ingredient content or low amount of degradation products). This also requires high (storage) stability of the compositions, and cost-specific considerations must also be taken into account.

[0037] Against this background, it is an object of the present invention to provide an efficient process for producing a sterile composition which comprises oxybutynin or oxybutynin hydrochloride as the active ingredient and which is present in a preferably ready-to-use storage or application device, namely a piston syringe, wherein the previously described disadvantages of the prior art are to be at least largely avoided or at least mitigated.

[0038] In this context, one object of the present invention is to provide a method for this purpose, which results in a ready-to-use storage or application device containing an aqueous composition with oxybutynin or oxybutynin hydrochloride as the active substance in sterile form, wherein the composition, even after sterilization, not only exhibits a high degree of sterility but also a high or unchanged active ingredient content or, at most, a low content of corresponding degradation products. In particular, within the scope of the present invention, any potential loss of active ingredient in the composition or the potential formation of degradation products of the active ingredient should be minimized or reduced to a pharmaceutically acceptable level.

[0039] In this regard, the present invention is intended, in particular, to provide such a method that is equally cost-effective, particularly with regard to the materials and components used in the method. Furthermore, the materials and components used in the method are also intended to be easy to handle, particularly with regard to sterilization treatments to be carried out. Furthermore, the method provided by the invention is also intended to be applicable and scalable on an industrial or large-scale basis.

[0040] Within the scope of the present invention, a method is also intended to be provided by which a correspondingly germ-free composition with oxybutynin or oxybutynin hydrochloride as the active substance is produced, which, while being highly germ-free or sterile, also exhibits high efficacy and tolerability. This is also intended to ensure improved application safety and improved (storage) stability or shelf life. In particular, a ready-to-use product is to be provided on this basis, in which the corresponding composition is incorporated into a storage or application device, namely a corresponding (disposable) syringe or plunger syringe.

[0041] Furthermore, according to a further object of the present invention, a drug-containing composition as such or a storage or application device filled with the drug-containing composition, specifically in the form of a (disposable) syringe or plunger syringe, is to be provided. In this context, the (disposable) syringe or plunger syringe is to be accessible to a sterilization process in an improved manner, ensuring effective sterilization while maintaining the stability of the contents in the form of the drug-containing composition.

[0042] To achieve the above-described problem, the present invention thus proposes - according to the aspect of the present invention - a method for producing a sterile oxybutyn-containing composition in a preferably ready-to-use piston syringe according to claim 1; advantageous developments and refinements of this aspect of the invention are the subject of the subclaims relating to the method.

[0043] Also described - according to an aspect described here - is a sterile oxybutynin-containing composition, which is intended in particular for use in the prophylactic or therapeutic treatment of neurogenic bladder dysfunction.

[0044] Also described again - according to an aspect described herein - is the plunger syringe which comprises the sterile oxybutynin-containing composition described herein.

[0045] Also described - according to an aspect of the present invention described here - is the packaging unit which contains the piston syringe described here with the composition.

[0046] Furthermore - according to an aspect described here - kits ( Kit of parts ) described.

[0047] Also described again - according to an aspect described herein - is the use of a special piston syringe in a method for producing a sterile oxybutyn-containing composition.

[0048] Finally, according to one aspect described herein, the use of heat sterilization, in particular steam sterilization, to provide a sterile oxybutynin-containing composition is described.

[0049] It goes without saying that embodiments, forms of embodiment, advantages and the like which are listed below for the purpose of avoiding repetition with regard to one aspect of the invention naturally also apply accordingly with regard to the other aspects of the invention without this requiring separate mention.

[0050] Furthermore, with regard to the following description of the present invention, the features of the present invention cited in connection with the specific configurations, embodiments, advantages, examples, or the like are also deemed to be disclosed in their combination. Thus, higher-level combinations of individual or multiple features cited for respective configurations, embodiments, application examples, or the like are also deemed to be disclosed.

[0051] With regard to all relative or percentage weight-related information mentioned below, in particular quantity or concentration information, it should also be noted that, within the scope of the present invention, these must be selected by the person skilled in the art in such a way that, in total, including all components or ingredients, in particular as defined below, they add up to 100% or 100% by weight; however, this is self-evident to the person skilled in the art.

[0052] Furthermore, the person skilled in the art may deviate from the concentration, weight, quantity and range specifications given below, depending on the application or the individual case, without departing from the scope of the present invention.

[0053] Furthermore, all values ​​or parameters mentioned below, or similar, can generally be determined using standardized or explicitly specified determination procedures, or otherwise using determination or measurement methods familiar to those skilled in the art. Unless otherwise stated, the underlying values ​​or parameters are determined under standard conditions (i.e., in particular, at a temperature of 20 °C and / or at a pressure of 1,013.25 hPa or 1.01325 bar) or atmospheric pressure.

[0054] With that in mind, the present invention is explained in detail below: Within the scope of the present invention and as detailed below, the applicant has found that when using special (disposable) syringes or piston syringes based on polypropylene (PP) as syringe material, particularly during heat sterilization, in particular steam sterilization, to obtain sterile oxybutynin-containing compositions, there is also a migration or incorporation of oxybutynin into the syringe body, wherein such migration or incorporation is controlled or compensated according to the invention, as is the case for a possible degradation of oxybutynin in the composition to corresponding degradation products. In addition, the present invention also focuses on controlling the pH value or related changes in the composition.Within the scope of the present invention, ready-to-use products based on sterile oxybutyn-containing compositions can be provided using polypropylene-based piston syringes.

[0055] The subject of the present invention - according to the aspect of the invention - is thus a process for producing a sterile oxybutyn-containing composition in a preferably ready-to-use piston syringe, in particular a disposable piston syringe, and / or for producing a preferably ready-to-use, sterile piston syringe filled with an oxybutyn-containing composition, in particular a disposable piston syringe, wherein the piston syringe has a syringe body, in particular a syringe cylinder, on the one hand, and a syringe piston with a piston stopper on the other hand, wherein the syringe body, in particular a syringe cylinder, is formed from a polypropylene (PP), and wherein the oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), is designed as a sterile aqueous composition, in particular a terminally sterilized composition, and the following specification requirements (i) and (ii) and / or (iii), preferably (i), (ii) and(iii), comprising: (i) a predetermined specification concentration of oxybutynin, preferably in the form of the hydrochloride (oxybutynin hydrochloride, oxybutynin HCl), with a predetermined deviation of at most ± 5%, based on the concentration of oxybutynin, (ii) a predetermined specification pH with a predetermined deviation of at most ± 0.5 pH units, (iii) a predetermined maximum specification amount of oxybutynin degradation product(s), in particular reactively induced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively induced oxybutynin degradation product(s), preferably phenylcyclohexylhydroxyacetic acid (impurity D); wherein the method comprises the following steps: a) providing an oxybutyn-containing starting composition in the syringe and / or filling the syringe with an oxybutyn-containing starting composition and subsequently b) heat sterilization, in particular steam sterilization, preferably steam sterilization,preferably terminal (heat, steam, water vapor) sterilization of the oxybutynin-containing starting composition in the plunger syringe and / or the plunger syringe filled with the oxybutynin-containing starting composition to obtain the sterile oxybutynin-containing final composition in the preferably ready-to-use plunger syringe and / or to obtain the preferably ready-to-use, sterile plunger syringe filled with the oxybutynin-containing composition, wherein the migration and / or incorporation of the oxybutynin into the syringe body, in particular the syringe barrel, and / or into the plunger stopper occurring in the process, in particular in process step b), and / or the degradation of the oxybutynin occurring in the process, in particular in process step b), in particular the reactive degradation of the oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation, preferably the degradation to phenylcyclohexylhydroxyacetic acid (impurity D),is controlled and / or compensated in such a way and with the proviso that the sterile oxybutynin-containing final composition obtained after carrying out process step b) meets the above-mentioned specifications (i) and (ii) and / or (iii), preferably (i), (ii), and(iii), and the sterile oxybutynin-containing final composition is obtained in the preferably ready-to-use plunger syringe or the preferably ready-to-use, sterile plunger syringe filled with the oxybutynin-containing final composition, wherein the migration and / or incorporation of the oxybutynin into the syringe body and / or into the plunger stopper occurring in the process, in particular in process step b), and / or the degradation occurring in the process, in particular in process step b), in particular the reactive degradation of the oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation of the oxybutynin, preferably the degradation to phenylcyclohexylhydroxyacetic acid, is controlled and / or monitored by at least one of the following measures and / or steps (1), (2), (3) and / or (4),in particular prevented and / or minimized and / or compensated: (1) setting and / or using an increased concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, in the starting composition compared to the specification concentration and / or specification amount of oxybutynin; (2) setting a pH value in the starting composition that deviates from the specification pH value, in particular an increased pH value; (3) setting and / or selection of the sterilization conditions, in particular selected from the group of sterilization type, sterilization duration, sterilization temperature, sterilization pressure, sterilization atmosphere and combinations thereof, preferably setting and / or selection of the F0 value of the sterilization; (4) finishing and / or treatment, in particular coating, of the syringe body, preferably the inner wall of the syringe body,and / or the piston stopper with at least one migration and / or degradation reducing agent.

[0056] The following should be noted in addition to understanding the aforementioned specifications (i) and (ii) and to understanding patent claim 1: Specifications (i) and (ii) each represent an individual value (i.e., a specific (individual) value) limited by the deviation specified for the respective specification. For example, if the specification concentration of oxybutynin according to (i) is specified as 1 mg / ml, this results in a specified specification concentration regime of 1 mg / ml ± 5%, or of (1 ± 0.05) mg / ml, or of 0.95 to 1.05 mg / ml. The same applies to the specification pH according to (ii): For example, if a specification pH according to (ii) of 4.0 is specified, this results in a specified specification pH regime of 4.0 ± 0.5 or from 3.5 to 4.5.

[0057] According to the present aspect, the invention also relates to a previously defined process for producing a sterile oxybutyn-containing composition in a preferably ready-to-use piston syringe, in particular a disposable piston syringe, and / or for producing a preferably ready-to-use, sterile piston syringe filled with an oxybutyn-containing composition, in particular a disposable piston syringe, wherein the piston syringe has a syringe body, in particular a syringe cylinder, on the one hand, and a syringe piston with a piston stopper on the other hand, wherein the syringe body, in particular a syringe cylinder, is formed from a polypropylene (PP), and wherein the oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), is designed as a sterile aqueous composition, in particular a terminally sterilized composition, and the following specification requirements (i) and (ii) and / or (iii), preferably (i), (ii) and(iii), has: (i) predetermined specification concentration of oxybutynin, preferably in the form of the hydrochloride (oxybutynin hydrochloride, oxybutynin HCl): 0.5 mg / ml to 2 mg / ml with a maximum deviation of ± 5%, based on the concentration of oxybutynin, preferably 1 mg / ml with a maximum deviation of ± 0.05 mg / ml (i.e., the predetermined specification concentration of oxybutynin is to be selected or specified as an individual value or as a specific (individual) value from the aforementioned range of 0.5 mg / ml to 2 mg / ml, the maximum deviation of ± 5% relating to the individual value or specific (individual) value to be selected or specified), (ii) predetermined specification pH value: 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, most preferably 3.8 to 4,2 (ie wherein the predetermined specification pH value is to be selected or specified as an individual value or as a specific (individual) value from the aforementioned ranges from 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, very particularly preferably 3.8 to 4.2, wherein the maximum deviation of ± 0.5 relates to the individual value or specific (individual) value to be selected or specified), (iii) predetermined specification amount of oxybutynin degradation product(s), in particular reactively induced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively induced oxybutynin degradation product(s), preferably phenylcyclohexylhydroxyacetic acid (impurity D): at most 0.5 wt.%, in particular at most 0.2 wt.%, based on the total amount of oxybutynin used,preferably oxybutynin hydrochloride; wherein the method comprises the following steps: a) providing an oxybutynin-containing starting composition in the syringe and / or filling the syringe with an oxybutynin-containing starting composition and subsequently b) heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, of the oxybutynin-containing starting composition in the syringe and / or the syringe filled with the oxybutynin-containing starting composition to obtain the sterile oxybutynin-containing final composition in the preferably ready-to-use syringe and / or to obtain the preferably ready-to-use, sterile syringe filled with the oxybutynin-containing composition, wherein the migration and / or incorporation of the oxybutynin into the syringe body occurring in the method, in particular in method step b),in particular syringe barrels, and / or in the plunger stopper, and / or the degradation of the oxybutynin occurring in the process, in particular in process step b), in particular the reactive degradation of the oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation, preferably the degradation to phenylcyclohexylhydroxyacetic acid (impurity D), is controlled and / or compensated in such a way and with the proviso that the sterile oxybutynin-containing final composition obtained after carrying out process step b) meets the above-mentioned specifications (i) and (ii) and / or (iii), preferably (i), (ii), and (iii), and the sterile oxybutynin-containing final composition is obtained in the preferably ready-to-use plunger syringe or the preferably ready-to-use, sterile plunger syringe filled with the oxybutynin-containing final composition.

[0058] The following should be added to understand the aforementioned specifications (i) and (ii) and to understand patent claim 2: As already explained above for the understanding of patent claim 1, the specifications (i) and (ii) each represent an individual value (i.e., a specific (individual) value) which is limited by the deviation stated for the respective specification. For example, if the specification concentration of oxybutynin according to (i) is specified as 1 mg / ml, this results in a specified specification concentration regime of 1 mg / ml ± 5%, or of (1 ± 0.05) mg / ml, or of 0.95 to 1.05 mg / ml. The same applies to the specification pH according to (ii): For example, if a specification pH according to (ii) of 4.0 is specified, this results in a specified specification pH regime of 4.0 ± 0.5 or from 3.5 to 4.5.The same applies to the specification parameter (iv) described below.

[0059] With regard to the above information on the specification concentration of oxybutynin, the maximum deviation of ± 5% or ± 0.05 mg / ml is to be understood as the maximum deviation (so that all intermediate values ​​are also included in the deviations stated; i.e. the specification ± 5% covers the range from + 5% to - 5% or the specification ± 0.05 mg / ml covers the range from + 0.05 mg / ml to - 0.05 mg / ml, so that, for example, for a given specification concentration of oxybutynin or oxybutynin hydrochloride of 1 mg / ml, this results in a corresponding specification concentration value range of 0.95 mg / ml to 1.05 mg / ml, whereby the corresponding intermediate values ​​are also included). The same applies to the specification pH value according to (ii) and the specification parameter (iv) described below.

[0060] The special process according to the invention, including the heat sterilization provided according to the invention, in particular steam sterilization, leads to an effective sterilization of an oxybutynin-containing (final) composition in the underlying piston syringe, in particular a disposable piston syringe, wherein the resulting sterile oxybutynin-containing (final) composition can be adjusted in a targeted manner to specific specifications, such as in particular in the form of the concentration of oxybutynin, the pH value and the amount of oxybutynin degradation products, as previously mentioned.Based on the method according to the invention, sterile oxybutynin-containing compositions with defined properties, in particular with regard to a predetermined active ingredient concentration and a predetermined pH value, can be provided, while simultaneously having a low content of degradation products, which are consequently safe to use with high efficacy in relation to the underlying indication due to the existing sterility and the low amount of degradation products.

[0061] It is entirely surprising within the scope of the present invention that a sterile oxybutynin-containing composition with defined properties with regard to the underlying specifications can be obtained in a piston syringe with a syringe body, in particular syringe barrel, made of or based on polypropylene (PP), since in this regard the prior art has hitherto assumed that polypropylene-based piston syringes have a high level of incompatibility with the active ingredient oxybutynin or oxybutynin hydrochloride, in particular with regard to degradation or the formation of oxybutynin degradation products, in particular during sterilization. Furthermore, the applicant has – entirely surprisingly – found within the scope of the present invention that with regard to the active ingredient oxybutynin or oxybutynin hydrochloride, a particularly thermally induced orparticularly during heat sterilization, preferably steam sterilization, there is migration or incorporation of oxybutynin, particularly in the form of the free amine base, in particular in the syringe body made of polypropylene (PP) and also in the plunger stopper, wherein this migration or incorporation of oxybutynin can be controlled or compensated for within the scope of the present invention by the targeted technical measures as stated in the context of the method according to the invention, so that on this basis the previously stated specifications with regard to the sterile oxybutynin-containing (final) composition can be achieved or maintained and in particular there is only a slight loss of active substance during sterilization.

[0062] The applicant was also able to show, surprisingly, that within the scope of the present invention, on the basis of the very specific process control according to the invention with the targeted sequence and design of the underlying process steps, on the one hand a particularly thermally induced degradation of oxybutynin to corresponding oxybutynin degradation products, in particular in the form of impurity D, can be reduced or prevented or, as such, occurs only to a small or pharmaceutically acceptable extent.

[0063] In this context, the applicant was also able to demonstrate that at least essentially no degradation of oxybutynin occurs, or that the degradation in question is prevented or reduced to a pharmaceutically acceptable minimum when the invention is followed, as explained below. Furthermore, the applicant was able to demonstrate for the first time that, with regard to the use of polypropylene-based plunger syringes, migration or incorporation of oxybutynin occurs and that this can be surprisingly controlled, compensated, or evened out, so that overall a storage-stable sterile oxybutynin-containing composition or plunger syringes filled therewith can be provided in compliance with the specifications.

[0064] Based on the method according to the invention, corresponding (disposable) syringes or piston syringes based on polypropylene or with corresponding syringe bodies made of polypropylene can thus be used for the first time as storage or application devices for oxybutynin-containing compositions, also with regard to the provision of correspondingly sterile compositions using heat sterilization and in particular steam sterilization methods.

[0065] Thus, within the scope of the method according to the invention, the disadvantages associated with polypropylene-based (disposable) syringes, in particular piston syringes, can be overcome, whereby both the degradation of the active substance to corresponding degradation products, in particular to the contaminant D, and the migration or incorporation of oxybutynin into the piston syringe or syringe body discovered by the applicant can be controlled or compensated accordingly. As explained in more detail below, the control or compensation can be achieved, for example, by specifying or adjusting the concentration or amount of oxybutynin or oxybutynin hydrochloride, by setting or specifying the pH value in the underlying starting composition, or by setting or selecting the sterilization conditions, as well as by specifically equipping or treating the piston syringe or syringe body.

[0066] Within the scope of the present invention, it has therefore been possible overall to provide a sterile oxybutynin-containing composition (final composition) which is introduced into a piston syringe based on polypropylene and which, even after heat sterilization, in particular steam sterilization, has a defined or predetermined concentration of oxybutynin or oxybutynin hydrochloride at a similarly adjusted or predetermined pH value and a defined amount of impurities. According to the invention, the focus is in particular on preventing the loss of oxybutynin which occurs during heat sterilization, in particular steam sterilization, which is caused in particular by migration or incorporation into the syringe material and by the degradation or formation of the corresponding hydrolysis product, in particular in the form of impurity D, by targeted measures with regard to the underlying starting composition orto control or compensate for the heat sterilization used or the underlying syringe material, with the aim of minimizing the loss of active ingredient in the composition and maintaining a certain pH value.

[0067] As stated below, the applicant has also found in this context that the loss of active substance occurring during sterilization also depends on the pH value and the amount or concentration of the active substance in the form of oxybutynin or oxybutynin hydrochloride in the initial composition and can be controlled thereby.

[0068] In particular, the process according to the invention also enables the provision of a specification-compliant oxybutyn-containing composition in sterile form.

[0069] Within the scope of the method according to the invention, the migration or incorporation of oxybutynin into the plunger plug used in the syringe can also be controlled or compensated for. This interaction can be further reduced by selecting special materials for the plunger plug, as explained below. Likewise, degradation of oxybutynin associated with the plunger plug can also be further reduced.

[0070] The same applies to the closure element described below. Consequently, according to the invention, migration or incorporation of oxybutynin into the closure element can be controlled or compensated for, and / or degradation of oxybutynin associated with the closure element can be further reduced, as also described below.

[0071] A further advantage of the process according to the invention is that the use of polypropylene-based piston syringes allows for the use of an overall cost-effective storage or application device as primary packaging, which also results in cost optimization of the underlying process as a whole and thus also of the resulting products. Furthermore, the polypropylene-based piston syringes used according to the invention also exhibit application-specific advantages with regard to high scratch resistance and high temperature resistance, combined with high mechanical strength and reduced material rigidity. This is one of the main reasons why the process according to the invention can also be implemented efficiently in industrial or large-scale applications.

[0072] Without wishing to be limited to or relying on this theory, the migration or incorporation of oxybutynin, particularly in the syringe body or in the plunger stopper, discovered within the scope of the present invention and specifically controlled or compensated, or the degradation of oxybutynin, particularly occurring during heat sterilization, is also related to the chemical-structural or physico-chemical properties of oxybutynin.

[0073] Thus, oxybutynin can react or be degraded in aqueous solutions on the basis of both acidic and basic hydrolysis to the corresponding free acid, namely phenylcyclohexylhydroxyacetic acid (cf. the following structural formula (2)), whereby this impurity is referred to as impurity D ("Impurity D" or "imp. D")Oxybutynin (see structural formula (1) below) is generally used in aqueous solutions as a hydrochloride due to its improved solubility in aqueous media. HCl coordinates to the free amine base, whereby in acidic solutions the active substance is present particularly in its complexed form according to structural formula (3) (the same applies to the solid). An equilibrium of the active ingredient according to (1) and (3) can be established in the composition, also depending on the pH value.

[0074] The figure above shows the hydrolysis of oxybutynin (structural formula 1) to impurity D in the form of phenylcyclohexylhydroxyacetic acid (structural formula 2).

[0075] The above structural formula (3) shows the water-soluble form of oxybutynin, namely in the form of oxybutynin hydrochloride.

[0076] Oxybutynin according to structural formula (1) and oxybutynin hydrochloride according to structural formula (3) also differ – equally without wishing to be limited to or relying on this theory – in their polarity, solubility, and affinity for apolar surfaces. In this context, the applicant has equally surprisingly found that, particularly during heat sterilization, oxybutynin in the form of structural formula (1) in particular migrates to a greater or greater extent into the polypropylene-based syringe material or is incorporated therein, particularly due to its lower polarity compared to substance (3). This effect can generally also be dominant over degradation, as the applicant also found.

[0077] In this context, the applicant was also able to observe a reduction in the pH value of the oxybutynin-containing composition upon migration, storage or loss of oxybutynin, which - without wishing to be limited to or relying on this theory - may be caused by the fact that oxybutynin, in particular, is removed from the composition in the form of the free amine base.

[0078] Furthermore, the applicant was able to show that at lower initial pH values ​​of the composition to be sterilized, a lower loss of oxybutynin or a reduced reduction in the pH value occurs during heat sterilization.

[0079] Within the scope of the present invention, with regard to the sterilization of the oxybutyn-containing composition carried out according to the method, heat sterilization, preferably steam sterilization, is also targeted and purposefully based, by means of which excellent sterilization results can be achieved according to the invention with simultaneous high product stability. The heat sterilization process, in particular steam sterilization, is one of the thermal sterilization processes, whereby efficient sterilization is ensured through the use of heat energy. With regard to the steam sterilization preferred according to the invention, the associated use of (water) steam is also of great importance, since this ensures good energy or heat transfer to the components or goods to be sterilized.In particular, during the condensation of the steam on the cooler sterilization material, the heat energy or quantity is transferred to the syringe to be sterilized or the oxybutynin-containing composition to be sterilized, thereby killing or irreversibly inactivating microorganisms or the like. Within the scope of the heat sterilization used according to the invention, in particular steam sterilization, a so-called complete or joint and simultaneous sterilization of the syringe used with the oxybutynin-containing composition contained therein is thus ensured. This represents a further advantage, for example, compared to sterile filling or the like, since the terminal sterilization preferably provided according to the invention further increases sterilization reliability.

[0080] In general, the term (heat) sterilization or (steam) sterilization, as used in the context of the present invention, is understood to mean in particular the killing or irreversible inactivation of microorganisms, germs, viruses or the like that are present on or in an object to be sterilized, including their resting stages or persistent forms, such as endospores or the like. Since the complete elimination or inactivation of all pathogens on or in an article or object cannot be guaranteed with complete certainty from a purely statistical perspective, an article or an object to be sterilized is generally considered sterile if the probability of contamination with reproducible pathogens does not exceed a certain value. In this regard, a value of at most 1 : 10 6< or 10 -6< can be cited.This means that out of 1 million units of an item to be sterilized, at most one unit is non-sterile (e.g. if this unit is contaminated with a colony forming unit (CFU) of a microorganism or pathogen, or if the residual content of pathogens per unit of an item to be sterilized is at most 10 -6< CFU, which means that the probability of a non-sterile unit is 1 : 10 6<). An item can therefore be considered sterile in particular if the theoretical value of no more than one living microorganism is present in 10 6< (1 million) sterilized units of the final product. This is also generally stated by the . Sterility A ssurance Level (SAL) spoken. Reference can also be made to the following explanations.

[0081] Within the scope of the present invention, a procedure is thus particularly carried out in such a way that a syringe prefilled with the oxybutynin-containing composition, based on polypropylene or with a syringe body, in particular a syringe barrel, made of polypropylene, in which the oxybutynin-containing composition is incorporated or present, is preferably terminally heat-sterilized, in particular steam-sterilized. This leads to high sterilization reliability and efficiency.

[0082] Within the scope of the present invention, as previously stated, the focus is on the use of (disposable) syringes or piston syringes based on polypropylene. As previously stated, the invention provides that the piston syringe has a syringe body, in particular a syringe barrel, on the one hand, and a syringe piston with a piston stopper on the other hand, wherein the syringe body, in particular a syringe barrel, is formed from and / or consists of a polypropylene (PP). In this regard, corresponding piston syringes or syringe bodies or syringe barrels based on a polypropylene with the product name ExxonMobil ®< PP 1013 H1 be used.

[0083] According to the invention, the formulation according to which the syringe body, in particular the syringe barrel, is made of polypropylene (PP) is to be understood in particular such that the syringe body, in particular the syringe barrel, comprises the polypropylene in an amount of at least 90 wt.%, in particular at least 95 wt.%, preferably at least 99 wt.%, more preferably at least 99.5 wt.%, based on the syringe body, in particular the syringe barrel, and preferably consists at least substantially thereof or consists entirely thereof. In this regard, the invention can generally provide for the syringe body, in particular the syringe barrel, to contain small amounts of further ingredients, such as stabilizers, processing aids, dyes, plastic additives or the like.According to the invention, it can be provided, in particular, that the syringe body, in particular the syringe barrel, comprises or consists of polypropylene in an amount of at least substantially 100% by weight, based on the syringe body, in particular the syringe barrel. It is therefore particularly preferred if the syringe body, in particular the syringe barrel, consists at least substantially, preferably entirely, of polypropylene.

[0084] As far as the method according to the invention is concerned, the migration and / or incorporation of oxybutynin into the syringe body, in particular the syringe barrel, and / or the plunger stopper, occurring in the method, in particular in method step b), and / or the degradation occurring in the method, in particular in method step b), in particular the reactive degradation of oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation of oxybutynin, preferably the degradation to phenylcyclohexylhydroxyacetic acid (impurity D), is controlled and / or monitored, in particular prevented and / or minimized or compensated, by at least one of the following measures and / or steps (1), (2), (3) and / or (4): (1) Setting and / or using an increased concentration and / or amount (excess weight) of oxybutynin, preferably in the form of hydrochloride, in the starting composition compared to the specification concentration and / or specification amount of oxybutynin; (2) Setting a pH value in the starting composition that deviates from the specification pH value, in particular an increased pH value; (3) Setting and / or selecting the sterilization conditions, in particular selected from the group of sterilization type, sterilization duration, sterilization temperature, sterilization pressure, sterilization atmosphere and combinations thereof, preferably setting and / or selecting the F0 value of the sterilization (lethality value);(4) Equipping and / or treating, in particular coating, the syringe body, in particular the syringe barrel, preferably the inner wall of the syringe body, in particular the syringe barrel, and / or the plunger stopper with at least one migration- and / or degradation-reducing agent.

[0085] According to the invention, it is particularly preferred that at least measure or step (1) is carried out. According to the invention, it can thus be provided in particular that at least measure or step (1) and Measure or step (2), if necessary in combination with measure or step (3) and / or (4), is carried out.

[0086] According to the invention, it is equally advantageous if at least measure or step (1) and Measure or step (2) must be carried out.

[0087] Thus, it is further preferred according to the invention that at least measure or step (1) andMeasure or step (2) and Measure or step (3), if necessary in combination with measure or step (4), must be carried out.

[0088] As regards measure or step (1), the present invention can be carried out in particular as follows: Thus, according to the invention, in particular in the case of measure and / or step (1), the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, in the starting composition can be selected or adjusted by 1% to 20%, in particular 2% to 15%, preferably 2% to 15%, preferably 3% to 10%, particularly preferably 4% to 8%, very particularly preferably 4% to 6%, above the specification concentration and / or specification amount of oxybutynin, preferably in the form of the hydrochloride, of the final composition.In addition, in particular in the case of measure and / or step (1), the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, in the starting composition can be adjusted to a value in the range from 101% to 120%, in particular in the range from 102% to 115%, preferably in the range from 102% to 115%, preferably in the range from 103% to 110%, particularly preferably in the range from 104% to 108%, very particularly preferably in the range from 104% to 106%, of the specification concentration and / or the specification amount of oxybutynin, preferably in the form of the hydrochloride, of the final composition.Also, in particular in the case of measure and / or step (1), the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, in the starting composition can be adjusted to a value in the range from 0.51 mg / ml to 3.5 mg / ml, in particular in the range from 0.55 mg / ml to 3 mg / ml, preferably in the range from 0.6 mg / ml to 2.5 mg / ml, preferably in the range from 0.8 mg / ml to 2.2 mg / ml, particularly preferably in the range from 0.9 mg / ml to 1.8 mg / ml, even more preferably in the range from 1.05 mg / ml to 1.1 mg / ml, very particularly preferably from about 1.05 mg / ml or else from about 1.1 mg / ml.

[0089] According to the invention, it is particularly possible to proceed in such a way that oxybutynin, preferably in the form of the hydrochloride, is used in excess in the starting composition or in a higher amount compared to the (final) composition (excess weight) in order to balance or compensate for the migration, incorporation, or degradation occurring during heat sterilization, in particular steam sterilization. It is also important to note that the measures according to the invention prevent excessive degradation and thus minimize the formation of undesirable degradation products despite the higher amount of oxybutynin.

[0090] As regards measure or step (2), the present invention can be carried out in particular as follows: According to the invention, in particular in the case of measure and / or step (2), the pH of the starting composition can be selected and / or adjusted by 0.02 pH units to 2.4 pH units, in particular 0.05 pH units to 2.2 pH units, preferably 0.1 pH units to 2 pH units, more preferably 0.15 pH units to 1.8 pH units, more preferably 0.2 pH units to 1.6 pH units, most preferably 0.25 pH units to 1.4 pH units above the specification pH of the final composition. In addition, in particular in the case of measure and / or step (2), the pH of the starting composition can be selected and / or adjusted to 5% to 90%, in particular 5% to 85%, preferably 10% to 80%, preferably 10% to 75%, particularly preferably 15% to 70%, very particularly preferably 20% to 60%, above the specification pH of the final composition.In addition, in particular in the case of measure and / or step (2), the pH of the starting composition can be adjusted to a value in the range from 2.8 to 7.5, in particular in the range from 3.1 to 7, preferably in the range from 3.4 to 6.5, more preferably in the range from 3.5 to 6, particularly preferably in the range from 3.6 to 5.8, most preferably in the range from 3.9 to 5.

[0091] In general, in the case of measure and / or step (2), the pH of the starting composition can be adjusted using and / or by means of hydrochloric acid (HCl).

[0092] Within the scope of the present invention, with regard to measure or step (2), it is possible, in particular, to set or specify a higher pH value in the starting composition compared to the specification of the final composition. This can compensate for the reduction in pH associated with the migration or incorporation of oxybutynin or the degradation of oxybutynin.

[0093] As regards measure or step (3), the present invention can be carried out in particular as follows: Thus, in particular in the case of measure and / or step (3), heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out with an FO value in the range from 6 min to 45 min, in particular in the range from 8 min to 40 min, preferably in the range from 10 min to 38 min, preferably in the range from 11 min to 35 min, particularly preferably in the range from 15 min to 32 min, very particularly preferably in the range from 19 min to 30 min.Furthermore, in particular in the case of measure and / or step (3), the sterilization conditions can be set to or selected from an FO value in the range from 6 min to 45 min, in particular in the range from 8 min to 40 min, preferably in the range from 10 min to 38 min, more preferably in the range from 11 min to 35 min, particularly preferably in the range from 15 min to 32 min, most preferably in the range from 19 min to 30 min.

[0094] In this regard, the applicant was able to demonstrate that, while ensuring a high level of sterility, migration and degradation can be further controlled or minimised.

[0095] The FO value of heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, water vapor) sterilization, is used in particular to determine the thermal stress of a sample, whereby the FO value represents the equivalent stress of the sterilization carried out compared to sterilization at a reference temperature of approximately 121 °C and is specified in minutes. With regard to the FO value, all lethal effects of the heat sterilization carried out are summed or integrated over the course of the sterilization or the underlying sterilization program. An FO value of one minute corresponds to a thermal stress equivalent to one minute at a sterilization temperature of approximately 121 °C. The definition and setting or specification of the F0 value is well known to the person skilled in the art, so that no further explanation is required in this regard.

[0096] As regards measure or step (4), the present invention can be carried out in particular as follows: Thus, particularly in the case of measure or step (4), the finishing and / or treatment, in particular coating, of the syringe body, in particular the syringe barrel, preferably the inner wall of the syringe body, in particular the syringe barrel, and / or the plunger stopper can be carried out with a silicon-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate, in particular by siliconization or silicatization. Particularly in the case of measure and / or step (4), the migration- and / or degradation-reducing agent can therefore be a silicon-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate.

[0097] For example, a coating can be applied with a silicone oil based on dimethicone, for example using silicone oil Ph. Eur. "Dimeticone" 1,000 mPas.

[0098] The relevant equipment or treatment takes place in particular before the syringe body is filled with the starting composition.

[0099] By equipping the syringe body, in particular the syringe barrel, in a targeted or purpose-oriented manner, the migration or deposition of oxybutynin in the syringe body or syringe barrel can be further reduced, as surprisingly discovered by the applicant.

[0100] In a corresponding manner, within the scope of the present invention, the closure element described below can in principle also be treated and / or coated accordingly, preferably equally with a silicon-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate, in particular as a migration- and / or degradation-reducing agent.

[0101] According to the invention, plunger syringes, in particular syringe bodies, and / or plunger stoppers and / or closure elements treated and / or coated with a silicon-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate, can be used for the process.

[0102] Within the scope of the present invention, the procedure can be such that the migration and / or incorporation of oxybutynin into the syringe body, in particular the syringe barrel, and / or into the plunger stopper occurring in the process, in particular in process step b), and / or the degradation occurring in the process, in particular in process step b), in particular the reactive degradation of oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation of oxybutynin, preferably the degradation to phenylcyclohexylhydroxyacetic acid (impurity D), is controlled and / or monitored, in particular prevented and / or minimized and / or compensated, by at least one of the following measures and / or steps (1), (2), (3) and / or (4): (1) Setting and / or using an increased concentration and / or amount (excess weight) of oxybutynin, preferably in the form of the hydrochloride, in the starting composition compared to the specification concentration and / or specification amount of oxybutynin, preferably in the form of the hydrochloride, in particular wherein in the starting composition the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, is selected and / or set by 1% to 20%, in particular 2% to 15%, preferably 2% to 15%, preferably 3% to 10%, particularly preferably 4% to 8%, very particularly preferably 4% to 6%, above the specification concentration and / or specification amount of oxybutynin, preferably in the form of the hydrochloride;and / or in particular wherein in the starting composition the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, is adjusted to a value in the range from 101% to 120%, in particular in the range from 102% to 115%, preferably in the range from 102% to 115%, preferably in the range from 103% to 110%, particularly preferably in the range from 104% to 108%, very particularly preferably in the range from 104% to 106%, of the specification concentration and / or the specification amount of oxybutynin, preferably in the form of the hydrochloride;and / or in particular wherein in the starting composition the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, is adjusted to a value in the range from 0.51 mg / ml to 3.5 mg / ml, in particular in the range from 0.55 mg / ml to 3 mg / ml, preferably in the range from 0.6 mg / ml to 2.5 mg / ml, preferably in the range from 0.8 mg / ml to 2.2 mg / ml, particularly preferably in the range from 0.9 mg / ml to 1.8 mg / ml, even more preferably in the range from 1.05 mg / ml to 1.1 mg / ml, very particularly preferably from about 1.05 mg / ml or from about 1.1 mg / ml;(2) setting a pH value of the starting composition which differs from the specification pH value, in particular an increased pH value, in particular wherein the pH value of the starting composition is selected and / or set by 0.02 pH units to 2.4 pH units, in particular 0.05 pH units to 2.2 pH units, preferably 0.1 pH units to 2 pH units, preferably 0.15 pH units to 1.8 pH units, particularly preferably 0.2 pH units to 1.6 pH units, very particularly preferably 0.25 pH units to 1.4 pH units above the specification pH value of the final composition; and / or in particular wherein the pH of the starting composition is selected and / or adjusted to be 5% to 90%, in particular 5% to 85%, preferably 10% to 80%, more preferably 10% to 75%, particularly preferably 15% to 70%, most preferably 20% to 60%, above the specification pH;and / or in particular wherein the pH of the starting composition is adjusted to a value in the range from 2.8 to 7.5, in particular in the range from 3.1 to 7, preferably in the range from 3.4 to 6.5, more preferably in the range from 3.5 to 6, particularly preferably in the range from 3.6 to 5.8, most particularly preferably in the range from 3.9 to 5; wherein the pH of the starting composition is adjusted using and / or by means of hydrochloric acid (HCl);(3) Setting and / or selection of the sterilization conditions, in particular selected from the group of sterilization type, sterilization duration, sterilization temperature, sterilization pressure, sterilization atmosphere and combinations thereof, preferably setting and / or selection of the F0 value of the sterilization (lethality value), in particular wherein the heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization is carried out with a F0 value in the range from 6 min to 45 min, in particular in the range from 8 min to 40 min, preferably in the range from 10 min to 38 min, preferably in the range from 11 min to 35 min, particularly preferably in the range from 15 min to 32 min, very particularly preferably in the range from 19 min to 30 min;(4) Equipping and / or treating, in particular coating, the syringe body, in particular the syringe barrel, preferably the inner wall of the syringe body, in particular the syringe barrel, and / or the plunger stopper with at least one migration- and / or degradation-reducing agent, preferably a silicon-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate, in particular by means of siliconization or silicatization, and / or wherein the migration- and / or degradation-reducing agent is a silicon-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate; in particular wherein at least measure and / or step (1), optionally in combination with measure and / or step (2), (3) and / or (4), is carried out; and / or in particular wherein at least measure and / or step (1); andMeasure and / or step (2), optionally in combination with measure and / or step (3) and / or (4), are carried out; and / or in particular wherein at least measure and / or step (1) and Measure and / or step (2) and measure and / or step (3), where appropriate in combination with measure and / or step (4), are carried out.

[0103] Within the scope of the present invention, the migration and / or incorporation into the syringe body, in particular the syringe barrel, and / or the plunger stopper occurring in the process, in particular in process step b), may be caused by and / or induced by oxybutynin in the form of the free base, in particular oxybutynin in the form of the free amine base. Reference can also be made to the above explanations in this regard.

[0104] In this context, it may in particular be the case that the pH value is lowered or decreased as a result of the migration and / or incorporation of oxybutynin in the form of the free base, in particular oxybutynin in the form of the free amine base, into the syringe body, in particular the syringe barrel.

[0105] As also stated above, and without wishing to rely on or be limited by any theory in this regard, oxybutynin in the form of the free base (cf. structural formula (1) above) has a lower polarity than oxybutynin in the form of the hydrochloride (cf. structural formula (3) above), which can result in preferential migration into the apolar syringe material. Removing or reducing oxybutynin in the form of the free base in the composition results in a corresponding reduction in the pH of the underlying composition. As stated above, these effects can be compensated or balanced accordingly by the measures mentioned above, in order to achieve or ensure the equally previously stated specifications with regard to the final composition obtainable by the process.

[0106] According to the invention, it can also be such that the migration and / or incorporation of the oxybutynin into the syringe body, in particular the syringe barrel, and / or into the plunger stopper occurring in the process, in particular in process step b), and / or the degradation occurring in the process, in particular in process step b), in particular the reactive degradation of the oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation of the oxybutynin, preferably the degradation to phenylcyclohexylhydroxyacetic acid (impurity D), by adjusting the ratio of (i) oxybutynin in the form of the free base, in particular oxybutynin in the form of the free amine base, on the one hand, and (ii) oxybutynin in the form of the complexed and / or coordinated and / or salted and / or protonated base, in particular oxybutynin in the form of the complexed and / or coordinated and / or salted and / or protonated amine base, preferably oxybutynin in the form of the hydrochloride,is controlled and / or monitored, in particular prevented and / or minimized and / or compensated.,

[0107] In this context, it can in particular be such that the ratio is shifted towards (ii) oxybutynin in the form of the complexed and / or coordinated and / or salted and / or protonated base, in particular oxybutynin in the form of the complexed and / or coordinated and / or salted and / or protonated amine base, preferably oxybutynin in the form of the hydrochloride, preferably by adjusting, in particular lowering and / or reducing, the pH and / or by adjusting a particularly low pH, in particular to a pH in the range from 2.8 to 5, preferably in the range from 3.1 to 4.5, more preferably in the range from 3.2 to 4.2, in the starting composition and / or by adding an acid to the starting composition.

[0108] According to the invention, the migration or incorporation of (i) oxybutynin in the form of the free base into the syringe body or syringe barrel can be reduced by correspondingly low pH values ​​of the starting composition, insofar as there is a shift in the starting composition toward (ii) oxybutynin in the form of the complexed or coordinated or saline or protonated base. This is also accompanied, in particular, by a smaller decrease in the pH value or a smaller pH loss during sterilization, especially steam sterilization.

[0109] Within the scope of the present invention, it can furthermore be such that the migration and / or incorporation of the oxybutynin into the syringe body, in particular the syringe cylinder, and / or into the plunger stopper occurring in the process, in particular in process step b), is limited and / or adjusted to a value of at most 20 wt.%, in particular at most 15 wt.%, preferably at most 10 wt.%, more preferably at most 8 wt.%, particularly preferably at most 5 wt.%, of the concentration and / or amount of oxybutynin present in the starting solution or starting composition, preferably in the form of the hydrochloride.

[0110] According to the invention, it can also be the case, in particular, that the final composition or the final composition obtained by the process according to the invention, in particular the final composition obtained after process step (b), has a lower pH than the starting composition. In this case, without wishing to be limited to or invoke this theory, the pH reduction can be caused by, or be related to, the incorporation or migration of oxybutynin, in particular in the form of the free base, into the syringe body or syringe barrel. In particular, within the scope of the present invention, the lowering or reduction of the pH (pH loss) occurs in the process, in particular in process step b).

[0111] Within the scope of the process according to the invention, it may in particular be the case that the lowering or reduction of the pH (pH loss) of the final composition compared to the starting composition is set and / or limited to a maximum of 2 pH units, in particular a maximum of 1.6 pH units, preferably a maximum of 1.2 pH units, preferably a maximum of 0.8 pH units, particularly preferably a maximum of 0.6 pH units, very particularly preferably a maximum of 0.4 pH units.

[0112] Likewise, it can be provided according to the invention that the lowering or reduction of the pH value (pH loss) of the final composition compared to the starting composition is limited or adjusted to at most 30%, in particular at most 25%, preferably at most 20%, preferably at most 15%, particularly preferably at most 10%, very particularly preferably at most 5%, of the pH value of the starting composition.

[0113] As regards the final oxybutynin-containing composition obtained after completion of the process, it may meet or comply with further specifications: In particular, the starting composition can be an aqueous composition. Thus, the oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), can comprise, as a further specification (iv), at least one electrolyte, in particular an alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in particular in a predetermined specification amount in the range from 0.1 wt.% to 2 wt.%, in particular in the range from 0.5 wt.% to 1.5 wt.%, preferably in the range from 0.7 wt.% to 1.2 wt.%, preferably of about 0.9 wt.%, based on the final composition.In particular, the oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), can contain, as a further specification (iv), sodium chloride, calculated as sodium, in a predetermined specification concentration of (3.5 ± 0.5) mg / ml, in particular (3.5 ± 0.3) mg / ml, preferably (3.5 ± 0.1) mg / ml, more preferably about 3.5 mg / ml. In addition, the oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), can have, as a further specification (v), a predetermined specification amount of total degradation products of at most 1 wt.%, in particular at most 0.5 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride. The total degradation products also include, in particular, the aforementioned impurity D.

[0114] With regard to the process according to the invention, the starting composition can be designed as follows, in particular with regard to the stated specifications of the final composition: Thus, the starting composition can contain oxybutynin, preferably in the form of the hydrochloride, preferably in a concentration or amount in the range from 0.51 mg / ml to 3.5 mg / ml, in particular in the range from 0.55 mg / ml to 3 mg / ml, preferably in the range from 0.6 mg / ml to 2.5 mg / ml, preferably in the range from 0.8 mg / ml to 2.2 mg / ml, particularly preferably in the range from 0.9 mg / ml to 1.8 mg / ml, even more preferably in the range from 1.05 mg / ml to 1.1 mg / ml, very particularly preferably about 1.05 mg / ml or about 1.1 mg / ml. In addition, the starting composition can have a pH in the range of 2.8 to 7.5, in particular in the range of 3.1 to 7, preferably in the range of 3.4 to 6.5, more preferably in the range of 3.5 to 6, particularly preferably in the range of 3.6 to 5.8, most preferably in the range of 3.9 to 5. In this context, the pH can be adjusted using or by means of hydrochloric acid (HCl).In addition, the starting composition can optionally contain at least one electrolyte, in particular alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in particular in an amount in the range from 0.1 wt.% to 2 wt.%, in particular in the range from 0.5 wt.% to 1.5 wt.%, preferably in the range from 0.7 wt.% to 1.2 wt.%, preferably of about 0.9 wt.%, based on the starting composition, and / or wherein the starting composition can optionally comprise sodium chloride, calculated as sodium, in a predetermined specification concentration of (3.5 ± 0.5) mg / ml, in particular (3.5 ± 0.3) mg / ml, preferably (3.5 ± 0.1) mg / ml.

[0115] In addition, the initial composition can be formed as follows: Thus, the composition can be formed as an aqueous composition; wherein the starting composition contains oxybutynin, preferably in the form of the hydrochloride, preferably in an amount in the range from 0.02 wt% to 0.25 wt%, in particular in the range from 0.05 wt% to 0.2 wt%, preferably in the range from 0.08 wt% to 0.15 wt%, preferably of about 0.15 wt%, based on the starting composition; wherein the starting composition optionally contains at least one electrolyte, in particular alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in particular in an amount in the range from 0.1 wt% to 2 wt%, in particular in the range from 0.5 wt% to 1.5 wt%, preferably in the range from 0.7 wt% to 1.2 wt%, preferably of about 0.9 wt.-%, based on the starting composition; and wherein the starting composition optionally comprises hydrochloric acid, in particular for adjusting the pH, in particular used in the form of 10% hydrochloric acid and in an amount in the range from 0.001 wt.% to 0.01 wt.%, in particular 0.003 wt.% to 0.008 wt.%, based on the starting composition.

[0116] In addition, the piston syringe used in the method according to the invention can be designed as follows: Thus, the piston syringe, preferably the syringe body, in particular the syringe barrel, can have a volume, in particular a receiving volume for the oxybutynin-containing composition, in the range from 1 ml to 100 ml, in particular in the range from 2 ml to 50 ml, preferably in the range from 3 ml to 25 ml, preferably in the range from 4 ml to 25 ml, particularly preferably in the range from 6 ml to 20 ml, further preferably in the range from 8 ml to 15 ml, even more preferably in the range from 9 ml to 12 ml, very particularly preferably of about 10 ml.In particular, the piston syringe, preferably the syringe body, in particular the syringe barrel, can contain the oxybutynin-containing composition in an amount in the range from 1 ml to 100 ml, in particular in the range from 2 ml to 50 ml, preferably in the range from 3 ml to 25 ml, preferably in the range from 4 ml to 25 ml, particularly preferably in the range from 6 ml to 20 ml, further preferably in the range from 8 ml to 15 ml, even more preferably in the range from 9 ml to 12 ml, most preferably of about 10 ml.

[0117] As previously mentioned, the syringe body, in particular the syringe barrel, serves in particular to contain the underlying oxybutynin-containing composition.

[0118] Furthermore, the syringe plunger can be made of or consist of polypropylene (PP). In this regard, a polypropylene based on or in the form of ExxonMobil ®< PP 1013 H1be used.

[0119] Furthermore, as regards the piston plug of the piston syringe, this can generally be formed or consist of an elastomeric material, in particular of a rubber material and / or rubber material, preferably rubber material.

[0120] According to the invention, however, it is preferred if the plunger stopper and / or the closure element described below is formed from or consists of a halobutyl rubber, in particular a chlorobutyl rubber or a bromobutyl rubber, preferably a bromobutyl rubber. In this context, the applicant has found that, in particular during heat sterilization, there is a higher compatibility with oxybutynin or oxybutynin hydrochloride, so that the loss of oxybutynin or oxybutynin hydrochloride in the composition can be further reduced, in particular due to lower migration into the plunger stopper or the closure element.In addition, halobutyl rubber, especially bromobutyl rubber, as preferably used for the piston stopper in the present invention, offers further advantages, particularly with regard to its high heat stability, improved aging properties, and low gas permeability. Commercially available products can be used for the piston stopper (e.g., Datwyler V9340FM257 / 2 bromobutyl compound).

[0121] According to the invention, the wording according to which the piston stopper or the closure element is formed from a halobutyl rubber, in particular from a chlorobutyl rubber or from a bromobutyl rubber, preferably from a bromobutyl rubber, is to be understood in particular in such a way that the piston stopper or the closure element comprises the halobutyl rubber, in particular the chlorobutyl rubber or the bromobutyl rubber, preferably the bromobutyl rubber, in an amount of at least 90 wt.%, in particular at least 95 wt.%, preferably at least 99 wt.%, more preferably at least 99.5 wt.%, based on the piston stopper or the closure element, and preferably consists at least substantially thereof or consists entirely thereof. In this regard, it can basically be provided according to the invention that the piston stopper orthe closure element contains small amounts of other ingredients, such as stabilizers, processing aids, dyes, plastic additives, or the like. According to the invention, it can be provided, in particular, that the piston stopper or the closure element comprises or consists of the halobutyl rubber, in particular the chlorobutyl rubber or the bromobutyl rubber, preferably the bromobutyl rubber, in an amount of at least substantially 100% by weight, based on the piston stopper or the closure element. It is therefore particularly preferred if the piston stopper or the closure element consists at least substantially, preferably entirely, of halobutyl rubber, in particular chlorobutyl rubber or bromobutyl rubber, preferably the bromobutyl rubber.

[0122] According to an alternative embodiment, the invention can also generally provide for the syringe plunger to be formed integrally with the plunger stopper. In this context, the syringe plunger and plunger stopper can be formed from or consist of polypropylene.

[0123] In general, the piston syringe, in particular the syringe body, preferably the syringe cylinder, has a receiving and / or filling opening, in particular for filling the syringe body, in particular the syringe cylinder, with the oxybutyn-containing composition and / or in particular for preferably sealingly receiving the syringe piston with the piston stopper and / or in particular wherein the receiving and / or filling opening is closable with the syringe piston, in particular with the piston stopper, and / or is designed to be closable or is closed.

[0124] In addition, it can be provided according to the invention that the syringe body has an adapter, in particular for connecting an instillation device and / or for dispensing and / or applying the oxybutyn-containing composition (connection and / or dispensing adapter).

[0125] In this context, the syringe body can be designed in one piece (single-part), i.e. in particular it can form a unit that is one piece or connected to the adapter. In particular, the adapter can form a connected unit with the syringe body, in particular the syringe barrel, in particular a fixed and / or non-detachable unit, preferably a materially bonded unit. In this context, within the scope of the present invention, it can equally be the case that the adapter is connected to the syringe body, in particular the syringe barrel, in particular a fixed and / or non-detachable unit, preferably a materially bonded unit. In this context, according to the invention, it can, for example, be the case that the adapter is connected to the syringe body by means of casting, in particular injection molding, casting, extrusion or the like, in particular a fixed or non-detachable unit, preferably a materially bonded unit.

[0126] In the context of the present invention, the term "one-piece" or "single-part" or "connected, in particular firmly and / or non-detachably connected" is to be understood, with regard to the preferred embodiment of the syringe body or syringe barrel on the one hand with the adapter on the other hand, in particular in such a way that the syringe body is an inseparable or firmly connected unit based on the syringe barrel and adapter as an integrated part comprising the syringe plunger and the adapter. In other words, in the context of the present invention, the adapter on the one hand and the syringe barrel on the other hand can form a cohesive and firmly connected or permanent unit to form the syringe body. In particular, according to the invention, the adapter on the one hand and the syringe barrel on the other hand are firmly connected orcannot be detachably connected or separated from one another. In particular, the aforementioned terms are to be understood as meaning that the syringe barrel, on the one hand, and the adapter, on the other hand, cannot be separated from one another, cannot be separated from one another, or can only be separated without destruction, or only with destruction. In particular, the syringe barrel, on the one hand, and the adapter, on the other hand, as a syringe body, can form a structural or physical unit without any non-destructive possibility of detaching the adapter or separating these components.

[0127] In this regard, within the scope of the present invention, it may in particular be such that the syringe barrel and the adapter are formed from identical materials or that the syringe barrel and the adapter are made from the same material, namely polypropylene, and in particular form a uniform, inseparably connected body.

[0128] As explained below, within the scope of the present invention, it can be provided in particular that the adapter formed integrally with the syringe barrel has a stepped cone shape. Reference can also be made to the following explanations in this regard.

[0129] Furthermore, the adapter of the piston syringe used in the method according to the invention can be designed as follows: The adapter can have an outlet opening, in particular at the free end of the adapter and / or in particular for dispensing and / or applying the oxybutyn-containing composition. In this context, the adapter can have an inlet opening, in particular in the transition region between the adapter and the syringe barrel and / or in particular for receiving the oxybutyn-containing composition from the syringe barrel. Furthermore, the adapter can be hollow.Furthermore, the adapter may have a cavity, in particular a passage channel, located between the outlet opening of the adapter and the inlet opening of the adapter, in particular for the outlet of the oxybutyn-containing composition, in particular wherein the cavity, in particular a passage channel, extends from the inlet opening of the adapter to the outlet opening of the adapter and / or connects the inlet opening to the outlet opening.

[0130] The adapter can further be tapered or tapered in the outlet direction and / or toward the outlet opening of the adapter. Furthermore, the adapter can have a decreasing and / or diminishing circumference, in particular an outer circumference, and / or a decreasing and / or diminishing diameter, in particular an outer diameter, in the outlet direction and / or toward the outlet opening of the adapter.

[0131] Within the scope of the present invention, the adapter can be designed in particular as follows: According to the invention, the adapter can be nozzle-shaped or designed as a nozzle, in particular as a conical or cylindrical nozzle, preferably without a thread, preferably as a Luer slip, or with a thread, in particular a screw thread, preferably as a Luer lock. In this regard, reference can also be made to the corresponding standards according to DIN EN 80369-7 and DIN EN 20594-1. Furthermore, the adapter can be conical or stepped cone-shaped, preferably stepped cone-shaped. In this context, the adapter can be designed such that the circumference, in particular outer circumference, or the diameter, in particular outer diameter, of the adapter decreases in the outlet direction or in the direction of the outlet opening of the adapter. In particular, the adapter can be designed as a stepped cone adapter.In this context, the adapter can have a number of steps in the range from 2 steps to 40 steps, in particular in the range from 3 steps to 30 steps, preferably in the range from 5 steps to 25 steps, preferably in the range from 8 steps to 20 steps, particularly preferably in the range from 10 steps to 15 steps. Furthermore, in this context, the circumference, in particular the outer circumference, and / or the diameter, in particular the outer diameter, of the steps of the adapter can decrease in the outlet direction and / or in the direction of the outlet opening of the adapter.In addition, in this context, the ratio of the diameter, in particular the outer diameter, of the adapter at the inlet opening of the adapter to the diameter, in particular the outer diameter, of the adapter at the outlet opening of the adapter can be in a range from 1.1 to 15, in particular in a range from 1.25 to 10, preferably in a range from 1.5 to 5, more preferably in a range from 2 to 4, particularly preferably in a range from 2.25 to 3.

[0132] According to the invention, the term "stepped cone-shaped" is understood in particular to mean a design of the adapter such that the circumference, in particular outer circumference, or the diameter, in particular outer diameter, of the adapter decreases in the discharge direction of the composition starting from the inlet opening in the direction of the outlet opening by forming individual or successive steps or in a step-like manner.

[0133] According to the invention, the adapter can thus be designed as a stepped cone adapter. As previously mentioned, this can, in particular, be a stepped cone adapter formed integrally with the syringe body.

[0134] In addition, the circumference, in particular the outer circumference, and / or the diameter, in particular the outer diameter, of the steps of the adapter can decrease in the outlet direction and / or in the direction of the outlet opening of the adapter.

[0135] Within the scope of the present invention, a piston syringe which is designed to be versatile with regard to the adapter can be used, wherein the concrete design can be tailored, so to speak, particularly against the background of the underlying range of applications or uses, wherein within the scope of the present invention, the possibility of connecting or attaching a large number of different application or instillation devices, in particular in the form of installation hoses or (urinary bladder) catheters, to the piston syringe used according to the invention can also be connected. The one-piece design of the syringe body or syringe cylinder and adapter which is optionally provided according to the invention has the advantage of improved handling of the piston syringe and at the same time reduces the risk of contamination, particularly in the area of ​​the adapter orwith regard to the oxybutynin-containing composition contained in the piston syringe, especially since the step of attaching or fastening a separate adapter to the syringe barrel prior to use is omitted and thus the application or instillation device can be connected directly to the piston syringe. This also reduces the risk of incorrect operation. The stepped design of the adapter, which is equally preferred according to the invention, ensures good fastening or fixation of the application or instillation device while at the same time improving handling. If necessary, the application or instillation device is guided over the adapter via a corresponding counterpart, or the adapter is guided into the application or instillation device, which is in particular tubular.

[0136] Furthermore, the piston syringe can have a particularly removable and / or removable and / or detachable closure element, in particular a closure cap (closure and / or sealing cap), preferably for particularly sealingly contacting the adapter and / or preferably for particularly sealingly placing it on the adapter and / or preferably for sealingly closing the outlet opening and / or the adapter.

[0137] The outlet opening or adapter can be closed with the closure element. In particular, within the scope of the present invention, the outlet opening or adapter is closed at least during sterilization and preferably also during filling of the syringe with the compositions or during provision of the compositions in the syringe.

[0138] In addition, the closure element can at least substantially completely and / or sealingly enclose or cover the adapter, in particular including the outlet opening.

[0139] In general, the closure element can thus close the outlet opening or the adapter. In particular, according to the invention, the piston syringe or the outlet opening is closed with the closure element within the scope of the method according to the invention.

[0140] As far as the closure element is concerned, it can also be designed as follows: In particular, the closure element can be designed to preferably bear sealingly against the adapter and / or to particularly sealably place it on the adapter and / or preferably to sealingly close the outlet opening of the adapter and / or to essentially completely and / or sealingly enclose the adapter. According to the invention, the closure element can in particular be cap-shaped or hat-shaped. In general, the closure element can have a receiving space, in particular for at least essentially completely receiving and / or at least essentially completely enclosing the adapter. In particular, according to the invention, it can behave in such a way that the closure element at least essentially completely encloses the adapter, which is in particular designed in the shape of a stepped cone.In addition, the closure element can be designed to bear against the adapter in a form-fitting and / or force-fitting manner, in particular with a frictional fit. Furthermore, the closure element can be designed to enclose the adapter in a form-fitting and / or force-fitting manner, in particular with a frictional fit. Within the scope of the present invention, the closure element can generally be formed from an elastomeric material, in particular from a rubber material and / or caoutchouc material. Preferably, the closure element can be formed from or consist of a halobutyl rubber, in particular from a chlorobutyl rubber or from a bromobutyl rubber, preferably from a bromobutyl rubber. Reference can also be made to the above explanations regarding the piston stopper.According to the invention, the closure element can further comprise a detaching and / or removal device, in particular a pulling device, preferably in the form of a particularly nipple-shaped extension and / or preferably for, in particular, manually detaching, in particular pulling, the closure element from the adapter. In this context, the detaching and / or removal device can be arranged on and / or in the region of the closed end and / or at the tip of the closure element and / or in the extension of the longitudinal axis of the closure element. In addition, the closure element can comprise at least one recess, in particular a notch, indentation and / or material taper, on its outer side.In this context, the recess can be longitudinally and / or linearly and / or rectilinearly formed, and moreover, the recess can be arranged to run at least substantially in the longitudinal direction and / or at least substantially parallel to the longitudinal axis of the closure element (7). Furthermore, the closure element can have two, three, four, five or more, in particular two, three or four, preferably four, recesses. In this context, the recesses can be arranged to run at least substantially equidistant from one another and / or at least substantially parallel to one another on the outer side of the closure element.

[0141] According to the invention, it can be provided in particular that the piston syringe or the adapter or the closure element is physically designed (ie with the exception of the material from which the piston syringe is formed, ie not the material properties of the piston syringe) according to DE 10 2020 130 032 A1 and / or according to DE 20 2020 106 531 U1, wherein the respective disclosure content of the aforementioned documents is hereby incorporated in its entirety by reference.

[0142] As previously stated, the invention also allows for the migration and / or incorporation of oxybutynin into the closure element occurring during the process, particularly in process step b), to be controlled and / or compensated for, specifically with the aforementioned proviso and / or by using the aforementioned measures and / or steps (1), (2), (3), and / or (4). However, this aspect is significantly less relevant, since the contact area with the composition is generally extremely small or minimal. This is also confirmed by the applicant's investigations.

[0143] In summary, according to the invention, the migration and / or incorporation of oxybutynin into the syringe body, in particular the syringe cylinder, and / or into the plunger stopper and / or into the closure element, occurring in the process, in particular in process step b), and / or the degradation of oxybutynin occurring in the process, in particular in process step b), in particular the reactive degradation of oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation, preferably the degradation to phenylcyclohexylhydroxyacetic acid (impurity D), can be controlled and / or compensated, equally with the aforementioned proviso and / or using the aforementioned measures and / or steps (1), (2), (3) and / or (4).

[0144] Furthermore, as regards the heat sterilization provided for in process step (b), this can be designed or carried out in particular as follows.

[0145] In general, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, water vapor) sterilization, can be carried out according to the invention under temperature application (heating).

[0146] According to the invention, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out at temperatures of at least 105 °C, in particular at least 110 °C, preferably at least 115 °C, preferably at least 120 °C.

[0147] In particular, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out at temperatures of at most 160°C, in particular at most 150°C, preferably at most 140°C, preferably at most 130°C.

[0148] According to the invention, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out at temperatures in the range from 105 °C to 160 °C, in particular in the range from 110 °C to 150 °C, preferably in the range from 115 °C to 140 °C, preferably in the range from 120 °C to 130 °C, particularly preferably at about 121 °C.

[0149] As stated above, heat sterilization according to the invention can be carried out with an F0 value in the range of 6 min to 45 min, in particular in the range of 8 min to 40 min, preferably in the range of 10 min to 38 min, preferably in the range of 11 min to 35 min, particularly preferably in the range of 15 min to 32 min, and most preferably in the range of 19 min to 30 min. Reference can also be made to the above explanations.

[0150] In particular, the heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out for a (total) period of at least 1 min, in particular of at least 2 min, preferably of at least 3 min, preferably of at least 4 min, particularly preferably of at least 5 min, very particularly preferably of at least 6 min.

[0151] In addition, the heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, water vapor) sterilization, can be carried out for a (total) period of at most 600 min, in particular of at most 500 min, preferably of at most 400 min, preferably of at most 350 min, particularly preferably of at most 300 min, very particularly preferably of at most 250 min.

[0152] Likewise, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out for a (total) period in the range from 1 min to 600 min, in particular in the range from 2 min to 500 min, preferably in the range from 3 min to 400 min, preferably in the range from 4 min to 350 min, particularly preferably in the range from 5 min to 300 min, most particularly preferably in the range from 6 min to 240 min.

[0153] According to the invention, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out under pressure.

[0154] According to the invention, it can also be provided that the heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, is carried out at a relative pressure in the range from 0.1 bar to 10 bar, in particular in the range from 0.5 bar to 5 bar, preferably in the range from 1 bar to 3.5 bar, preferably in the range from 1.5 bar to 3 bar.

[0155] In particular, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out at an absolute pressure in the range from 1.1 bar to 10 bar, in particular in the range from 1.5 bar to 6 bar, preferably in the range from 2 bar to 4.5 bar.

[0156] Likewise, the heat sterilization can be carried out in the presence of an atmosphere containing, in particular, pure steam and / or as a saturated steam process, or the steam sterilization can be carried out in the presence of a steam / gas mixture, in particular a mixture of steam with inert gas, in particular nitrogen, and / or oxygen, preferably a steam / air mixture.

[0157] In addition, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, water vapor) sterilization, can be carried out in a preferably closed sterilization device, in particular in a gas-tight pressure vessel, preferably in an autoclaving device (autoclave).

[0158] In this context, the sterilization atmosphere can be generated by injecting steam and / or steam / compressed air mixtures, preferably steam / compressed air mixtures, into the sterilization device.

[0159] In addition, the sterilization atmosphere in this context can be generated by injecting premixed steam / compressed air mixtures and / or by separately injecting steam and compressed air into the sterilization device.

[0160] According to the invention, it can also be provided that during heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, the steam is generated from distilled and / or demineralized water.

[0161] In addition, it can be provided according to the invention that during heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, water vapor) sterilization, the compressed air is generated from sterile air, in particular wherein the air is cleaned and / or sterilized by flowing through filters.

[0162] According to the invention, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, can be carried out under overkill conditions and / or at about 121 °C and / or for a period of at least 6 min, preferably of about 6 min, or of at least 20 min, preferably of about 20 min.

[0163] In addition, heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, water vapor) sterilization, can be carried out according to Pharmacopoea Europaea (Ph. Eur.), Chapter 5.1.1 (07 / 2017:50101), in particular under overkill conditions and / or at about 121 °C and / or for a period of at least 15 min, in particular of at least 20 min, preferably of about 20 min.

[0164] According to the invention, it has also proven advantageous if the heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, is carried out in multiple cycles, in particular wherein at least the final and / or terminal cycle is carried out under at least one of the aforementioned conditions. In this regard, it can be provided, in particular, that the final and / or terminal cycle is carried out under overkill conditions and / or at approximately 121°C and / or for a period of at least 6 minutes, preferably approximately 6 minutes, or at least 20 minutes, preferably approximately 20 minutes.

[0165] According to the invention, it can also be provided that the piston syringe filled with the oxybutyn-containing composition is or has been introduced into a particularly water-tight and / or germ-tight closed and / or sealed package, in particular a standby pack, in particular before carrying out heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization. In this regard, in particular a part of the packaging can be designed to be at least permeable to water vapor, in particular permeable to water vapor and / or gas. According to the invention, it can in particular be such that the packaging is sterilized equally when carrying out steam sterilization.

[0166] Particularly with regard to large-scale application, the invention can provide for a plurality of plunger syringes filled with the oxybutyn-containing composition to be sterilized simultaneously. In this context, it can be arranged in such a way that, preferably during the steam sterilization, several plunger syringes are combined on one (syringe) carrier.

[0167] The sterile oxybutynin-containing composition (final composition) obtained after completion of the process, in particular after process step b), and / or the sterile piston syringe filled with the oxybutynin-containing composition (final composition) obtained after completion of the process, in particular after process step b), can in particular have a SAL value ( S terility A ssurance L evel ) of at least 10 -5< , in particular at least 10 -6< , preferably at least 10 -7< .

[0168] In particular, it can be provided according to the invention that the sterilized or sterile oxybutynin-containing composition (final composition) or the piston syringe obtained in the process according to the invention and filled with the oxybutynin-containing composition is sterile according to DIN EN 566-1.

[0169] For further details on the heat sterilization, in particular steam sterilization, underlying the method according to the invention, reference can be made in particular to DE 10 2017 104 931 A1 and to WO 2018 / 145799 A1 belonging to the same patent family.

[0170] Reference can also be made to DE 10 2011 105 840 A1 as well as to WO 2012 / 136313 A2 and US 2014 / 093422 A1, which belong to the same patent family.

[0171] As previously stated, the process according to the invention provides a sterile oxybutynin-containing composition with high stability. In particular, the sterile oxybutynin-containing composition has a low content of impurities or degradation products.

[0172] In particular, the sterile oxybutynin-containing composition (final composition) meets the previously defined specifications, even after extended storage periods.

[0173] In this context, according to the invention, it can behave in particular as follows: Thus, according to the invention, it can be such that the sterile oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), meets the specified specifications (i) and (ii) and / or (iii), in particular (i), (ii) and(iii), even after storage of the sterile syringe filled with the oxybutynin-containing final composition at temperatures in the range of 25 °C to 40 °C, at a relative humidity in the range of 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months. In addition, the sterile oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), can meet the following specifications (i) and (ii) and / or (iii), in particular (i), (ii) and(iii), even after storage of the sterile syringe filled with the final composition containing oxybutynin at temperatures in the range from 25 °C to 40 °C, at a relative humidity in the range from 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.fulfill: (i) specified specification concentration of oxybutynin, preferably in the form of the hydrochloride (oxybutynin hydrochloride, oxybutynin HCl): 0.5 mg / ml to 2 mg / ml with a maximum deviation of ± 5%, based on the concentration of oxybutynin, preferably 1 mg / ml with a maximum deviation of ± 0.05 mg / ml, (ii) specified specification pH: 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, very particularly preferably 3.8 to 4.2, (iii) specified specification amount of oxybutynin degradation product(s), in particular reactively induced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively induced Oxybutynin degradation product(s), preferably phenylcyclohexylhydroxyacetic acid (impurity D): at most 0.5 wt.%, in particular at most 0.2 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride.In addition, the sterile oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), can meet the specified specification (iv), in particular the specified specification amount (iv) of electrolyte, in particular alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in the range from 0.1 wt.% to 2 wt.%, in particular in the range from 0.5 wt.% to 1.5 wt.%, preferably in the range from 0.7 wt.% to 1.2 wt.%, preferably from about 0.9 wt.-%, based on the final composition, and / or the specified specification concentration (iv) of sodium chloride, calculated as sodium, of (3.5 ± 0.5) mg / ml, in particular (3.5 ± 0.3) mg / ml, preferably (3.5 ± 0.1) mg / ml, more preferably about 3.5 mg / ml, even after storage of the sterile piston syringe filled with the oxybutyn-containing final composition at temperatures in the range from 25 °C to 40 °C, at a relative air humidity in the range from 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.In addition, according to the invention, the sterile oxybutynin-containing final composition obtained after completion of the process, in particular after process step b), has or meets the specified specification (v), in particular the specified specification amount of total degradation products of at most 1 wt.%, in particular at most 0.5 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride, even after storage of the sterile piston syringe filled with the oxybutynin-containing final composition at temperatures in the range from 25 °C to 40 °C, at a relative air humidity in the range from 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.

[0174] With regard to the design of the method according to the invention according to the present aspect, reference can also be made to the following explanations regarding the further aspects, which apply accordingly.

[0175] Furthermore, according to an aspect described here, the sterile oxybutynin-containing composition (final composition) is also described, in particular for use in the prophylactic and / or therapeutic treatment of neurogenic bladder dysfunctions, in particular neurogenic bladder emptying disorders, preferably neurogenic bladder dysfunctions associated with detrusor hyperactivity and / or detrusor-sphincter dyssynergia, wherein the oxybutynin-containing composition is obtainable or obtained by the process according to the invention; and / or wherein the oxybutynin-containing composition is or has been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-)sterilized, by the process according to the invention.

[0176] According to this aspect, the presently described sterile oxybutynin-containing composition (final composition) is also for use in the prophylactic and / or therapeutic treatment of neurogenic bladder dysfunctions, in particular neurogenic bladder emptying disorders, preferably neurogenic bladder dysfunctions associated with detrusor hyperactivity and / or detrusor-sphincter dyssynergia, in particular the previously defined composition, wherein the oxybutynin-containing composition is present in a preferably ready-to-use piston syringe, in particular a disposable piston syringe, wherein the piston syringe has a syringe body, in particular a syringe barrel, on the one hand, and a syringe piston with a piston stopper on the other hand, wherein the syringe body, in particular a syringe barrel, is formed from a polypropylene (PP), and wherein the oxybutynin-containing composition is designed as a sterile aqueous composition, in particular a terminally sterilized composition, and the following specification requirements (i) and (ii) and / or (iii), preferably (i), (ii) and(iii), has: (i) predetermined specification concentration of oxybutynin, preferably in the form of the hydrochloride (oxybutynin hydrochloride, oxybutynin HCl): 0.5 mg / ml to 2 mg / ml with a maximum deviation of ± 5%, based on the concentration of oxybutynin, preferably 1 mg / ml with a maximum deviation of ± 0.05 mg / ml, (ii) predetermined specification pH: 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, very particularly preferably 3.8 to 4.2, (iii) predetermined specification amount of oxybutynin degradation product(s), in particular reactively induced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively induced Oxybutynin degradation product(s), preferably phenylcyclohexylhydroxyacetic acid (impurity D): not more than 0.5% by weight, in particular not more than 0.2% by weight.-%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride; wherein the oxybutynin-containing composition contained in the syringe, including the syringe, has been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-)sterilized.

[0177] The oxybutynin-containing composition described herein may additionally comprise, as a further specification (iv), at least one electrolyte, in particular alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in particular in a predetermined specification amount in the range from 0.1 wt.% to 2 wt.%, in particular in the range from 0.5 wt.% to 1.5 wt.%, preferably in the range from 0.7 wt.% to 1.2 wt.%, preferably of about 0.9 wt.%, based on the final composition.

[0178] In particular, the oxybutynin composition may contain, as a further specification (iv), sodium chloride, calculated as sodium, in a predetermined specification concentration of (3.5 ± 0.5) mg / ml, in particular (3.5 ± 0.3) mg / ml, preferably (3.5 ± 0.1) mg / ml, preferably about 3.5 mg / ml.

[0179] Furthermore, as a further specification (v), the oxybutynin-containing composition can have a specified specification amount of total degradation products of at most 1 wt.%, in particular at most 0.5 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride. As previously stated, the specification amount of total degradation products also includes impurity D.

[0180] In the present case, it is particularly provided that the piston plug is formed from an elastomeric material, in particular from a rubber material and / or rubber material, preferably rubber material. In the present case, it is preferred that the piston plug is formed from or consists of a halobutyl rubber, in particular from a chlorobutyl rubber or a bromobutyl rubber, preferably from a bromobutyl rubber.

[0181] As regards the composition described herein, it may be or have been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-) sterilized, under at least one of the conditions previously defined for the process according to the invention.

[0182] In the present case, it can be provided in particular that the oxybutynin-containing composition with an FO value in the range from 6 min to 45 min, in particular in the range from 8 min to 40 min, preferably in the range from 10 min to 38 min, preferably in the range from 11 min to 35 min, particularly preferably in the range from 15 min to 32 min, very particularly preferably in the range from 19 min to 30 min, is or has been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, water vapor-)sterilized.

[0183] In particular, the composition may be or have been heat sterilized, in particular steam sterilized, preferably steam sterilized, preferably terminally (heat, steam, steam) sterilized, under overkill conditions and / or at about 121°C and / or for a period of at least 6 min, preferably of about 6 min, or of at least 20 min, preferably of about 20 min.

[0184] In the present case, it can be provided in particular that the composition is or has been heat-sterilised, in particular steam-sterilised, preferably steam-sterilised, preferably terminally (heat-, steam-, steam-)sterilised, in accordance with Pharmacopoea Europaea (Ph. Eur.), Chapter 5.1.1 (07 / 2017:50101), in particular under overkill conditions and / or at about 121 °C and / or for a period of at least 15 minutes, in particular of at least 20 minutes, preferably of about 20 minutes.

[0185] With regard to the composition described here, it is particularly the case that the composition, including the relevant piston syringe, is or has been heat-sterilised, in particular steam-sterilised, preferably steam-sterilised, preferably terminally (heat-, steam-, steam-)sterilised.

[0186] The composition described here is characterized overall by defined specifications and their implementation and maintenance (even for longer storage times), in particular as a result of the process according to the invention for its production, so that the process according to the invention is also directly reflected in the composition according to the invention.

[0187] In particular, the composition is also characterized by a high (storage) stability: In the present case, it can behave in such a way that the oxybutynin-containing composition does not meet the specified specifications (i) and (ii) and / or (iii), in particular (i), (ii) and(iii), even after storage of the sterile syringe filled with the oxybutyn-containing composition at temperatures in the range of 25 °C to 40 °C, at a relative humidity in the range of 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.

[0188] In addition, it may also be the case that the oxybutynin-containing composition does not meet the following specification requirements (i) and (ii) and / or (iii), in particular (i), (ii) and(iii), even after storage of the sterile syringe filled with the oxybutyn-containing composition at temperatures in the range of 25 °C to 40 °C, at a relative humidity in the range of 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months, has or satisfies: (i) specified specification concentration of oxybutynin, preferably in the form of the hydrochloride (oxybutynin hydrochloride, oxybutynin HCl): 0.5 mg / ml to 2 mg / ml with a maximum deviation of ± 5%, based on the concentration of oxybutynin, preferably 1 mg / ml with a maximum deviation of ± 0.05 mg / ml, (ii) specified specification pH: 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, very particularly preferably 3.8 to 4.2, (iii) specified specification amount of oxybutynin degradation product(s), in particular reactively induced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively induced Oxybutynin degradation product(s), preferably phenylcyclohexylhydroxyacetic acid (impurity D): at most 0.5 wt.%, in particular at most 0.2 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride.

[0189] In particular, the oxybutynin-containing composition can meet the specified specification (iv), in particular the specified specification amount (iv) of electrolyte, in particular alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in the range from 0.1 wt.% to 2 wt.%, in particular in the range from 0.5 wt.% to 1.5 wt.%, preferably in the range from 0.7 wt.% to 1.2 wt.%, preferably of about 0.9 wt.%, based on the final composition, and / or the specified specification concentration (iv) of sodium chloride, calculated as sodium, of (3.5 ± 0.5) mg / ml, in particular (3.5 ± 0.3) mg / ml, preferably (3.5 ± 0.1) mg / ml, preferably about 3.5 mg / ml, even after storage of the sterile piston syringe filled with the oxybutynin-containing composition at temperatures in the range from 25°C to 40°C, at a relative humidity in the range of 60% to 75% and at a pressure of 1.013.25 mbar of at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.

[0190] Likewise, the oxybutynin-containing composition can have or meet the specified specification (v), in particular the specified specification amount of total degradation products of at most 1 wt.%, in particular at most 0.5 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride, even after storage of the sterile piston syringe filled with the oxybutynin-containing composition at temperatures in the range from 25 °C to 40 °C, at a relative humidity in the range from 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.

[0191] In addition, the oxybutynin-containing composition and / or the sterile syringe filled with the oxybutynin-containing composition may have a SAL value ( S terility A ssurance) of at least 10 -5< , in particular at least 10 -6< , preferably at least 10 -7< .

[0192] In the present case, the neurogenic bladder dysfunction is generally accompanied by or characterized by detrusor overactivity and / or detrusor-sphincter dyssynergia, in particular with an overactive detrusor.

[0193] In particular, neurogenic bladder dysfunction may be associated with or caused by a spinal cord injury, particularly paraplegia, spina bifida, diabetes, multiple sclerosis, stroke or Parkinson's disease.

[0194] The present invention also equally describes the sterile oxybutynin-containing composition for use in the prophylactic and / or therapeutic treatment of neurogenic bladder dysfunctions, in particular neurogenic bladder emptying disorders, preferably neurogenic bladder dysfunctions associated with detrusor hyperactivity and / or detrusor-sphincter dyssynergia, in particular wherein the neurogenic bladder dysfunctions are associated with and / or characterized by detrusor overactivity and / or detrusor-sphincter dyssynergia, in particular with an overactive detrusor, and / or wherein the neurogenic bladder dysfunctions are associated with or caused by a spinal cord injury, in particular paraplegia, spina bifida, diabetes, multiple sclerosis, stroke or Parkinson's disease.

[0195] In particular, the composition described herein can be intended or prepared for instillation or for preferably topical application into the urogenital area, in particular into the urinary bladder.

[0196] Furthermore, the oxybutynin-containing composition described herein can be intended or prepared for administration or instillation or, preferably, topical application into the urogenital tract, in particular into the urinary bladder. In particular, the oxybutynin-containing composition can be administered by instillation or topical application into the urogenital tract, in particular into the urinary bladder.

[0197] With regard to further embodiments of the composition described here, reference can also be made to the explanations on the other aspects, which apply accordingly in this case.

[0198] Furthermore, according to a further aspect described here, the piston syringe, in particular a disposable piston syringe, is also described, wherein the piston syringe has a syringe body, in particular a syringe cylinder, on the one hand, and a syringe piston with a piston stopper on the other hand, wherein the syringe body, in particular a syringe cylinder, is formed from a polypropylene (PP), wherein the plunger syringe is filled with a sterile oxybutynin-containing composition (final composition), in particular for use in the prophylactic and / or therapeutic treatment of neurogenic bladder dysfunctions, in particular neurogenic bladder emptying disorders, preferably neurogenic bladder dysfunctions associated with detrusor hyperactivity and / or detrusor-sphincter dyssynergia, in particular as defined above, wherein the plunger syringe is obtainable or obtained by a method according to a method as defined above; and / or wherein the oxybutynin-containing composition contained in the plunger syringe, including the plunger syringe, is or has been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-)sterilized, according to the method defined above.

[0199] In particular, according to this aspect, the piston syringe, in particular a disposable piston syringe, is also described here, wherein the piston syringe has a syringe body, in particular a syringe cylinder, on the one hand, and a syringe piston with a piston stopper on the other hand, wherein the syringe body, in particular a syringe cylinder, is formed from a polypropylene (PP), in particular a piston syringe as defined above, wherein the plunger syringe is filled with a sterile oxybutynin-containing composition (final composition), in particular for use in the prophylactic and / or therapeutic treatment of neurogenic bladder dysfunctions, in particular neurogenic bladder emptying disorders, preferably neurogenic bladder dysfunctions associated with detrusor hyperactivity and / or detrusor-sphincter dyssynergia, wherein the oxybutynin-containing composition is designed as a sterile aqueous composition, in particular a terminally sterilized composition, and the following specification requirements (i) and (ii) and / or (iii), preferably (i), (ii) and(iii), has: (i) predetermined specification concentration of oxybutynin, preferably in the form of the hydrochloride (oxybutynin hydrochloride, oxybutynin HCl): 0.5 mg / ml to 2 mg / ml with a maximum deviation of ± 5%, based on the concentration of oxybutynin, preferably 1 mg / ml with a maximum deviation of ± 0.05 mg / ml, (ii) predetermined specification pH: 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, very particularly preferably 3.8 to 4.2, (iii) predetermined specification amount of oxybutynin degradation product(s), in particular reactively induced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively induced Oxybutynin degradation product(s), preferably phenylcyclohexylhydroxyacetic acid (impurity D): not more than 0.5% by weight, in particular not more than 0.2% by weight.-%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride; wherein the oxybutynin-containing composition contained in the syringe, including the syringe, is or has been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-)sterilized.

[0200] The oxybutynin-containing composition can in particular also have or meet the following specifications: Thus, as a further specification (iv), the oxybutynin-containing composition can comprise at least one electrolyte, in particular an alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in particular in a predetermined specification amount in the range from 0.1 wt.% to 2 wt.%, in particular in the range from 0.5 wt.% to 1.5 wt.%, preferably in the range from 0.7 wt.% to 1.2 wt.%, preferably of about 0.9 wt.%, based on the final composition, in particular in a predetermined specification amount. In addition, the oxybutynin-containing composition can contain, as a further specification (iv), sodium chloride, calculated as sodium, in a predetermined specification concentration of (3.5 ± 0.5) mg / ml, in particular (3.5 ± 0.3) mg / ml, preferably (3.5 ± 0.1) mg / ml, preferably about 3.5 mg / ml.Furthermore, the oxybutynin-containing composition can, as a further specification (v), have a specified specification amount of total degradation products of at most 1 wt.%, in particular at most 0.5 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride.

[0201] In the present case, the piston syringe, preferably the syringe body, in particular the syringe cylinder, can have a volume, in particular a receiving volume for the oxybutynin-containing composition, in the range from 1 ml to 100 ml, in particular in the range from 2 ml to 50 ml, preferably in the range from 3 ml to 25 ml, preferably in the range from 4 ml to 25 ml, particularly preferably in the range from 6 ml to 20 ml, further preferably in the range from 8 ml to 15 ml, even more preferably in the range from 9 ml to 12 ml, most preferably of about 10 ml.Likewise, the piston syringe, preferably the syringe body, in particular the syringe barrel, can contain the oxybutynin-containing composition in an amount in the range from 1 ml to 100 ml, in particular in the range from 2 ml to 50 ml, preferably in the range from 3 ml to 25 ml, preferably in the range from 4 ml to 25 ml, particularly preferably in the range from 6 ml to 20 ml, further preferably in the range from 8 ml to 15 ml, even more preferably in the range from 9 ml to 12 ml, most preferably of about 10 ml.

[0202] As far as the piston syringe described here is concerned, the syringe piston in question can be made of or consist of polypropylene in particular.

[0203] Furthermore, the piston plug can be formed from or consist of an elastomeric material, in particular from a rubber material and / or rubber material, preferably rubber material. According to a presently preferred embodiment, the piston plug can be formed from or consist of a halobutyl rubber, in particular from a chlorobutyl rubber or from a bromobutyl rubber, preferably from a bromobutyl rubber.

[0204] In the present case, it can be particularly such that the piston syringe, in particular the syringe body, preferably the syringe cylinder, has a receiving and / or filling opening, in particular for filling the syringe body, in particular the syringe cylinder, with the oxybutyn-containing composition and / or in particular for preferably sealingly receiving the syringe piston with the piston stopper and / or in particular wherein the receiving and / or filling opening is closable with the syringe piston, in particular with the piston stopper, and / or is designed to be closable and / or is closed.

[0205] Furthermore, it can be provided in the present case that the syringe body has an adapter, in particular for connecting an instillation device and / or for dispensing and / or applying the oxybutyn-containing composition.

[0206] In this context, it can be provided, in particular, that the syringe body is formed in one piece (single-part). In this context, it can equally be provided that the adapter forms a connected unit with the syringe body, in particular the syringe barrel, in particular a fixed and / or non-detachable unit, preferably a materially bonded unit. In this context, it can also be provided that the adapter is connected to the syringe body, in particular the syringe barrel, in particular a fixed and / or non-detachable unit, preferably a materially bonded unit.

[0207] In the present case, the adapter may have an outlet opening, particularly at the free end of the adapter and / or particularly for dispensing and / or applying the oxybutyn-containing composition. Furthermore, the adapter may have an inlet opening, particularly in the transition area between the adapter and the syringe barrel and / or particularly for receiving the oxybutyn-containing composition from the syringe barrel.

[0208] In particular, it is provided here that the adapter is hollow.

[0209] In particular, the adapter may have a cavity, in particular a passage channel, located between the outlet opening of the adapter and the inlet opening of the adapter, in particular for the outlet of the oxybutyn-containing composition. In this context, the cavity, in particular a passage channel, may extend from the inlet opening of the adapter to the outlet opening of the adapter or connect the inlet opening to the outlet opening.

[0210] In the present case, it can also be provided that the adapter is tapered or tapered in the outlet direction and / or in the direction of the outlet opening of the adapter.

[0211] In addition, the adapter can have a decreasing and / or diminishing circumference, in particular outer circumference, and / or a decreasing and / or diminishing diameter, in particular outer diameter, in the outlet direction and / or in the direction of the outlet opening of the adapter.

[0212] In this case, the adapter can also be designed as follows: The adapter can be nozzle-shaped or designed as a nozzle, in particular as a conical or cylindrical nozzle, preferably without a thread, preferably as a Luer slip, or with a thread, in particular a screw thread, preferably as a Luer lock. Furthermore, the adapter can be conical or stepped cone-shaped, preferably stepped cone-shaped. According to a presently preferred embodiment of the invention, the adapter can be designed as a stepped cone adapter. In this context, the adapter can have a number of steps in the range from 2 steps to 40 steps, in particular in the range from 3 steps to 30 steps, preferably in the range from 5 steps to 25 steps, preferably in the range from 8 steps to 20 steps, particularly preferably in the range from 10 steps to 15 steps.In this context, it can also be provided that the circumference, in particular the outer circumference, and / or the diameter, in particular the outer diameter, of the steps of the adapter decreases in the outlet direction and / or in the direction of the outlet opening of the adapter. It can also be provided in this context that the ratio of the diameter, in particular the outer diameter, of the adapter at the inlet opening of the adapter to the diameter, in particular the outer diameter, of the adapter at the outlet opening of the adapter is in a range from 1.1 to 15, in particular in a range from 1.25 to 10, preferably in a range from 1.5 to 5, more preferably in a range from 2 to 4, particularly preferably in a range from 2.25 to 3.

[0213] In the present case, it can be the case, in particular, that the piston syringe has a stepped cone-shaped adapter or a stepped cone adapter, wherein the stepped cone-shaped adapter or stepped cone adapter forms a connected, in particular fixedly or non-detachably connected, preferably materially connected, unit with the syringe body, in particular syringe cylinder, or wherein the adapter is formed in one piece with the syringe body, in particular syringe cylinder.

[0214] Furthermore, the piston syringe described here can be designed as follows: Thus, the piston syringe can have a particularly removable and / or detachable closure element, in particular a closure cap (closure and / or sealing cap), preferably for sealingly fitting against the adapter and / or preferably for sealingly placing onto the adapter and / or preferably for sealingly closing the outlet opening and / or the adapter. In particular, the outlet opening and / or the adapter is closed with the closure element. In particular, the piston syringe or the outlet opening and / or the adapter is closed with the closure element during implementation of the method according to the invention, in particular in method step b). In particular, the closure element can at least substantially completely and / or sealingly enclose the adapter, in particular together with the outlet opening.cover, in particular at least substantially over the entire outer surface and / or (outer) wall of the adapter and / or in particular at least substantially over the entire outlet opening of the adapter. In particular, the closure element can at least substantially completely enclose or cover the adapter, which is preferably designed as a stepped cone adapter, in a sealing manner, in particular at least substantially over the entire outer surface or (outer) wall of the adapter designed as a stepped cone adapter.

[0215] In the present case, it is therefore particularly provided that the closure element is designed to particularly sealingly bear against the adapter and / or to particularly sealingly place it on the adapter and / or preferably to sealingly close the outlet opening of the adapter and / or to substantially completely and / or sealingly enclose the adapter.

[0216] In general, the closure element can be cap- or hat-shaped.

[0217] In addition, the closure element can have a receiving space, in particular for at least substantially completely receiving and / or for at least substantially completely enclosing the adapter.

[0218] In particular, it can be provided in the present case that the closure element is designed to bear against the adapter in a form-fitting and / or force-fitting manner, in particular in a friction-fitting manner, and / or to be capable of bearing against it, and / or wherein the closure element encloses the adapter in a form-fitting and / or force-fitting manner, in particular in a friction-fitting manner, and / or to be capable of enclosing it.

[0219] In the present case, the closure element can generally be formed from an elastomeric material, in particular from a rubber material and / or caoutchouc material. According to a presently preferred embodiment, the closure element can be formed from or consist of a halobutyl rubber, in particular from a chlorobutyl rubber or from a bromobutyl rubber, preferably from a bromobutyl rubber.

[0220] According to a presently preferred embodiment, it can also be provided that the closure element has a detaching and / or removal device, in particular a pulling device, preferably in the form of a particularly nipple-shaped extension and / or preferably for in particular manually detaching, in particular pulling, the closure element from the adapter. In this context, the detaching and / or removal device can be arranged on and / or in the region of the closed end and / or at the tip of the closure element and / or in the extension of the longitudinal axis of the closure element.This can make the operation of the closure element easier overall, in particular with regard to gripping the closure element by hand and in particular removing the closure element from the adapter, in particular with regard to the use of the piston syringe described here when administering the sterile oxybutyn-containing composition.

[0221] In addition, the closure element can have at least one recess, in particular a notch, indentation and / or material taper, on its outer side. In this context, the recess can be longitudinal and / or linear and / or straight. In addition, the recess can be arranged to run at least substantially in the longitudinal direction and / or at least substantially parallel to the longitudinal axis of the closure element. In particular, the closure element can have two, three, four, five or more, in particular two, three or four, preferably four, recesses. The recesses can be arranged to run at least substantially equidistant from one another and / or at least substantially parallel to one another on the outer side of the closure element.

[0222] In the present case, the piston syringe, in particular the adapter or closure element, can be physically designed according to DE 10 2020 130 032 A1 and / or DE 20 2020 106 531 U1, as previously stated. In this regard, the advantages cited in the respective documents also apply to the respective embodiments in the present case.

[0223] As far as the piston syringe described here is further concerned, it can be or have been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-)sterilized, under at least one of the conditions defined above, in particular with regard to the method according to the invention.

[0224] In particular, the piston syringe can be or have been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-) sterilized, with an FO value in the range from 6 min to 45 min, in particular in the range from 8 min to 40 min, preferably in the range from 10 min to 38 min, preferably in the range from 11 min to 35 min, particularly preferably in the range from 15 min to 32 min, very particularly preferably in the range from 19 min to 30 min.

[0225] In addition, the syringe can be overkill -conditions and / or at about 121 °C and / or for a period of at least 6 min, preferably of about 6 min, or of at least 20 min, preferably of about 20 min, heat sterilized, in particular steam sterilized, preferably steam sterilized, preferably terminally (heat, steam, steam) sterilized.

[0226] Furthermore, it can be provided, in particular, that the plunger syringe is or has been heat-sterilized, in particular steam-sterilized, preferably steam-sterilized, preferably terminally (heat-, steam-, steam-)sterilized, in accordance with Pharmacopoea Europaea (Ph. Eur.), Chapter 5.1.1 (07 / 2017:50101), in particular under overkill conditions and / or at approximately 121°C and / or for a period of at least 15 minutes, in particular of at least 20 minutes, preferably of approximately 20 minutes. The heat-sterilization in this case, in particular steam-sterilization, refers to the composition, including the plunger syringe in which the composition is located.

[0227] In particular, the composition may also have the following properties with regard to the piston syringe described here or the piston syringe with the sterile composition incorporated therein: Thus, the sterile oxybutynin-containing composition may meet the specified specifications (i) and (ii) and / or (iii), in particular (i), (ii) and (iii), even after storage of the sterile syringe filled with the oxybutyn-containing composition at temperatures in the range of 25 °C to 40 °C, at a relative humidity in the range of 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.

[0228] In addition, the sterile oxybutynin-containing composition may meet the following specifications (i) and (ii) and / or (iii), in particular (i), (ii) and (iii), even after storage of the sterile syringe filled with the oxybutyn-containing composition at temperatures in the range of 25 °C to 40 °C, at a relative humidity in the range of 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months, have and / or comply with: (i) specified specification concentration of oxybutynin, preferably in the form of the hydrochloride (oxybutynin hydrochloride, oxybutynin HCl): 0.5 mg / ml to 2 mg / ml with a maximum deviation of ± 5%, based on the concentration of oxybutynin, preferably 1 mg / ml with a maximum deviation of ± 0.05 mg / ml, (ii) specified specification pH: 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, very particularly preferably 3.8 to 4.2, (iii) specified specification amount of oxybutynin degradation product(s), in particular reactively induced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively induced Oxybutynin degradation product(s), preferably phenylcyclohexylhydroxyacetic acid (impurity D): at most 0.5 wt.%, in particular at most 0.2 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride.

[0229] In particular, the sterile composition can meet the specified specification (iv), in particular the specified specification amount (iv) of electrolyte, in particular alkali metal salt, preferably alkali metal chloride, preferably sodium chloride (NaCl), in the range from 0.1 wt.% to 2 wt.%, in particular in the range from 0.5 wt.% to 1.5 wt.%, preferably in the range from 0.7 wt.% to 1.2 wt.%, preferably of about 0.9 wt.%, based on the final composition, and / or the specified specification concentration (iv) of sodium chloride, calculated as sodium, of (3.5 ± 0.5) mg / ml, in particular (3.5 ± 0.3) mg / ml, preferably (3.5 ± 0.1) mg / ml, preferably about 3.5 mg / ml, even after storage of the sterile syringe filled with the oxybutyn-containing composition at temperatures in the range from 25 °C to 40 °C, at a relative Humidity in the range of 60% to 75% and at a pressure of 1.013.25 mbar of at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.

[0230] In addition, the sterile oxybutynin-containing composition can have or meet the specified specification (v), in particular the specified specification amount of total degradation products of at most 1 wt.%, in particular at most 0.5 wt.%, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride, even after storage of the sterile piston syringe filled with the oxybutynin-containing composition at temperatures in the range from 25 °C to 40 °C, at a relative air humidity in the range from 60% to 75% and at a pressure of 1,013.25 mbar for at least 10 days, in particular at least 30 days, preferably at least 3 months, preferably at least 6 months, particularly preferably at least 12 months.

[0231] In addition, the oxybutynin-containing composition and / or the sterile syringe filled with the oxybutynin-containing composition may have a SAL value ( S terility A ssurance) of at least 10 -5< , in particular at least 10 -6< , preferably at least 10 -7< .

[0232] The piston syringe described here is particularly suitable for instillation or preferably topical application of the oxybutyn-containing composition into the urogenital area, in particular into the urinary bladder, in particular using a corresponding application or instillation device, in particular in the form of an instillation tube or the like or in the form of a (urinary bladder) catheter.

[0233] With regard to further embodiments of the piston syringe described here, reference can also be made to the explanations on the other aspects, which apply accordingly in this case.

[0234] Furthermore, according to a further aspect described herein, the packaging unit is also described, comprising at least one packaging and at least one piston syringe, in particular a disposable piston syringe, as defined above, wherein the piston syringe is introduced into the packaging or is present in the packaging.

[0235] In this context, the presently described packaging unit or the corresponding packaging with the corresponding piston syringe and the oxybutyn-containing composition may, in particular, be heat-sterilized, in particular steam-sterilized, according to the method according to the invention, as defined above. Furthermore, the presently described packaging unit may generally be designed as a standby pack. In particular, the presently described packaging unit may be closed or sealed in a water-tight and / or germ-tight manner. Furthermore, at least part of the packaging may be designed to be at least permeable to water vapor, in particular permeable to water vapor and / or gas.

[0236] For further explanations or configurations of the packaging unit described here, reference can also be made to the further explanations on the other aspects, which apply accordingly.

[0237] Also described again - according to a further aspect described herein - is the kit, in particular an application and / or instillation system, comprising (i) at least one oxybutynin-containing composition as defined above, present in a plunger syringe, in particular a disposable plunger syringe, in particular as defined above; (ii) (a) at least one application and / or instillation device connectable to the plunger syringe, in particular in the form of an instillation tube or the like, preferably in the form of a (urinary bladder) catheter, and / or (b) at least one connection device connectable to the plunger syringe for connection to an application and / or instillation device, in particular in the form of an instillation tube or the like, preferably in the form of a (urinary bladder) catheter; and optionally (iii) at least one application and / or instillation instruction.

[0238] According to this aspect, the further kit, in particular an application and / or instillation system, is also described here, comprising (i) at least one oxybutynin-containing composition, in particular as defined above, present in a piston syringe, in particular a disposable piston syringe, in particular as defined above; (ii) (a) at least one application and / or instillation device connectable to the piston syringe, in particular to the adapter of the piston syringe, in particular in the form of an instillation tube or the like, preferably in the form of a (urinary bladder) catheter; optionally (iii) an adapter counterpart for connecting the application and / or instillation device to the piston syringe, in particular to the adapter of the piston syringe; and optionally (iv) at least one application and / or instillation instruction.

[0239] The piston syringe described here with the corresponding sterile oxybutyn-containing composition, as defined above, can also be used in the form of the packaging unit described above.

[0240] With regard to further details in this regard, reference can also be made to the explanations on the other aspects, which apply accordingly.

[0241] Further still—according to a further aspect described herein—the use of a plunger syringe, in particular a disposable plunger syringe, in a method for producing a sterile oxybutyn-containing composition, in particular as defined above, is also described. Regarding the physical design of the plunger syringe, reference can be made to the above statements, which apply accordingly. The plunger syringe used here comprises a syringe body, in particular a syringe barrel, on the one hand, and a syringe plunger with a plunger stopper on the other hand, wherein the syringe body, in particular the syringe barrel, is made of polypropylene (PP).

[0242] In this regard, reference can also be made to the comments on the other aspects, which apply accordingly in this case.

[0243] In addition, according to a further aspect described herein, the use of heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably terminal (heat, steam, steam) sterilization, is described in a method for producing a sterile oxybutyn-containing composition, in particular as defined above, in a preferably ready-to-use piston syringe, in particular a disposable piston syringe, and / or for producing a preferably ready-to-use, sterile piston syringe filled with an oxybutyn-containing composition, in particular a disposable piston syringe, in particular as defined above.

[0244] With regard to the physical design of the plunger syringe, reference can be made to the above statements, which apply accordingly. The plunger syringe used here comprises a syringe body, in particular a syringe barrel, on the one hand, and a syringe plunger with a plunger stopper on the other hand, wherein the syringe body, in particular the syringe barrel, is made of polypropylene (PP).

[0245] For further relevant comments on the use described here according to this aspect, reference can also be made to the comments on the other aspects, which apply accordingly in this case.

[0246] The present invention is described below with reference to figures illustrating preferred embodiments or refinements. In connection with the explanation of this preferred embodiment or refinement of the present invention, which, however, is in no way limiting with respect to the present invention, further advantages, properties, aspects, and features of the present invention are also presented. Furthermore, for the Fig. 1 and Fig. 2 The reference symbols shown refer to the following list of reference symbols.

[0247] In the figure representations shows: Fig. 1 shows a schematic sectional view of a piston syringe obtained within the scope of the method according to the invention or a piston syringe filled with the sterile oxybutyn-containing composition; Fig. 2 shows a schematic sectional view of another piston syringe usable or obtained within the scope of the method according to the invention or a piston syringe filled with the sterile oxybutyn-containing composition; Fig. 2 shows a preferred embodiment of the present invention, according to which the piston syringe has a stepped cone-shaped adapter or a stepped cone adapter, wherein the syringe body is formed integrally with the adapter or according to which the adapter is connected to the syringe cylinder, in particular firmly or non-detachably connected, preferably materially connected; Fig. 2also shows a further embodiment of the invention, according to which the adapter, including the outlet opening, is closed or at least substantially completely covered with a closure element in the form of a closure cap; Fig. 3 is a graphic representation of the dependence of the reduction in pH (pH loss) present for sterile oxybutynin-containing compositions (final compositions) after carrying out the method according to the invention or after heat sterilization as a function of the initial pH (starting pH) of the starting composition before heat sterilization; Fig. 4 is a graphic representation of the dependence of the migration or incorporation rate of oxybutynin (loss of oxybutynin after heat sterilization) as a function of the pH of the starting composition (composition or solution before heat sterilization).

[0248] For further details on the embodiments and exemplary embodiments shown in the figures, reference can be made to the above statements and to the following supplementary statements on the present invention and to the statements on the exemplary embodiments, which apply accordingly with regard to the figures, in order to avoid unnecessary repetition. Fig. 1 and Fig. 2 The reference symbols shown refer to the following list of reference symbols.

[0249] Further embodiments, modifications and variations as well as advantages of the present invention will be readily apparent and achievable to a person skilled in the art upon reading the description, without departing from the scope of the present invention.

[0250] The following embodiments serve only to illustrate the present invention, without, however, limiting the present invention thereto. EXAMPLES AND FURTHER EMBODIMENTS OF THE PRESENT INVENTION: Objectives of the following series of tests

[0251] The present invention is to produce or provide a sterile oxybutynin-containing composition which meets the specifications listed in Table 1.

[0252] In this context, a 0.1% oxybutynin solution is used. The sterile oxybutynin-containing composition is to be provided in a ready-to-use disposable polypropylene syringe, whereby the disposable syringe and the oxybutynin-containing composition are to be thermally sterilized simultaneously. Due to its solubility, the active ingredient oxybutynin is used in the subsequent aqueous composition as hydrochloride (oxybutynin hydrochloride or oxybutynin HCl, structural formula (3)). Table 1 : Specifications of the sterile oxybutynin-containing composition after sterilization in the syringe (Impurity D = Phenylcyclohexylhydroxyacetic acid) parameter specification Oxybutynin content 95 - 105 % Contamination D ≤ 0.2 wt% further contaminants ≤ 0.2 wt% Total impurities ≤ 0.5 wt% PH value 3,5 - 4,2 background

[0253] The applicant's preliminary tests, which are not carried out on the basis of the method according to the invention, indicate that a non-sterile oxybutynin-containing solution in a cylinder treated by terminal thermal sterilization does not fall within the specified specification, whereas the stated values ​​are generally achieved for primary packaging materials or cylinders made of cycloolefin copolymer (COC) (see Table 1).

[0254] Preliminary tests show a loss of approximately 10% of oxybutynin after sterilization in a polypropylene syringe, as well as the formation of the hydrolysis product phenylcyclohexylhydroxyacetic acid (impurity D, structural formula 2) at 0.7%. Consequently, the specifications defined in Table 1 are not met. In contrast, the solution after sterilization in COC shows a lower loss. Oxybutynin in polypropylene storage devices (plunger syringes)

[0255] The above preliminary tests can be used as background or basis for the following inventive tests and questions.

[0256] Three aspects are particularly relevant, namely understanding the loss of oxybutynin concentration after sterilization, dependence of the formation of the hydrolysis product (impurity D), influence of the magnitude of the thermal stress on the above-mentioned points depending on the sterilization conditions, influence of the pH value on the parameters listed in Table 1.

[0257] The standard composition used is an oxybutynin-containing composition with the amounts specified in Table 2. Table 2: Oxybutynin-containing composition raw material Crowd Sodium chloride 0.9 wt.% 10% hydrochloric acid 0.0052 wt.% Oxybutynin HCl 0.1 wt.% Water 98.9948 wt.% Behavior of the specification parameters under different storage conditions without sterilization

[0258] The specification parameters of oxybutyn-containing compositions in polypropylene syringes are documented under two different storage conditions. The changes in the specification parameters over time are determined for oxybutyn-containing compositions with an initial pH of 3.8 and an initial pH of 4.2 (the initial pH values ​​represent values ​​in the upper and lower range of the specification specifications). The oxybutyn-containing compositions with the different initial pH values ​​are stored at 25 °C and 60% relative humidity (RH) and at 40 °C and 75% relative humidity, respectively. The specification parameters are determined after 10 days, 30 days, and 3 months and are listed in Table 3.

[0259] The following Table 3 shows the behavior of the specification parameters during different storage without sterilization of oxybutyn-containing compositions in polypropylene piston syringes.

[0260] It is shown that when the non-sterile oxybutynin-containing composition is stored in a polypropylene piston syringe without prior sterilization, the specifications are met over the entire period.

[0261] Furthermore, the data presented in Table 3 indicate that at higher pH values ​​and more intensive storage conditions (upper pH limit, 40 °C, 75% relative humidity, 30 days) a certain loss of oxybutynin is observed, which, however, is not accompanied by an increase in the degradation product D. Behavior of the specification parameters under different storage conditions after sterilization

[0262] In addition, the changes in the specification parameters after thermal sterilization of an oxybutyn-containing composition with an initial pH of 3.8 (initial pH in the lower range of the specification) are also determined.

[0263] The specification parameters are determined after 10 days, 30 days and 3 months and are listed in Table 4.

[0264] The following Table 4 shows the behavior of the specification parameters during different storage conditions of oxybutyn-containing compositions in polypropylene plunger syringes after sterilization (compared to the initial values ​​before sterilization).

[0265] Table 4 shows that, with an initial pH value in the lower range of the specification (approximately 3.8), a reduction or loss of 9.8% of oxybutynin is observed after sterilization. A corresponding decrease in the pH of the solution by 0.19 units occurs immediately after sterilization at time t0. The solution is therefore not compliant with the specifications. Upon storage for a period of 3 months under stressed conditions (40 °C, 75% relative humidity), it is evident that the decrease in the oxybutynin concentration levels off at approximately 7%. In this context, a return to a pH value of 3.8, which is compliant with the specifications, is achieved.

[0266] Compared to the non-sterile compositions, an increase of 0.018% in the hydrolysis product, impurity D, is evident after 10 days of storage at 25 °C and 60% relative humidity. However, the same magnitude is also observed in a non-sterile solution after 30 days at 40 °C and 75% relative humidity (see Table 3). This suggests that hydrolysis is a thermally induced process, but one of lesser significance overall. As can also be seen from Table 3, the unknown impurities are also at a level between that of the sterile and non-sterile solution. Mechanism of loss of oxybutynin after sterilization

[0267] As previously described and shown in Table 4, sterilization of an aqueous oxybutynin solution with a pH of 3.92 results in a 9.8% oxybutynin loss. However, this loss does not directly correlate with the concomitant increase in impurity D (oxybutynin hydrolysis product) or other unknown impurities.

[0268] As confirmed below, the oxybutynin could migrate from the aqueous solution into the PP packaging (i.e., into the polypropylene plunger syringe), particularly during sterilization. This would result in the reduction or loss of oxybutynin being thermally induced. Such an effect, which has not been described previously, would be completely surprising to the person skilled in the art.

[0269] The above assumption of migration of oxybutynin into the packaging can be confirmed especially in the case where (i) migration of impurity D into the packaging and consequent loss in the solution can be ruled out; and (ii) the reduction of oxybutynin is based on an unknown thermally induced degradation reaction, the degradation products of which cannot be detected using the validated HPLC method.

[0270] To exclude the possibility of a thermally induced degradation reaction of oxybutynin HCl leading to the formation of an unknown by-product that cannot be detected by a validated HPLC method, or of migration of the hydrolysis product D, the packaging material used (polypropylene cylinder and rubber stopper) is subjected to extraction with THF after sterilization, and the resulting extract is analyzed both qualitatively by thin-layer chromatography and quantitatively by HPLC.

[0271] Furthermore, the extract is subjected to aqueous microprocessing with diethyl ether at pH 4 to demonstrate that oxybutynin is present at pH 4 as the free amine base (structural formula (1)) in the organic phase (diethyl ether) or as the hydrochloride in the aqueous phase.

[0272] The results obtained after sterilization show that there is a decrease in oxybutynin in the solution of up to 9% at a pH of 3.8. It can be assumed that at pH 4, the majority of oxybutynin is present in the diethyl ether phase as a free amine base.

[0273] The extracts of the packaging materials with the respective analytical reference substances of oxybutynin and impurity D are analyzed on the thin-layer chromatography or TLC plate using the eluent cyclohexane / ethyl acetate 1:6.

[0274] Further tests show that the extract of the rubber parts does not contain oxybutynin, whereas the extract of the polypropylene cylinder does contain oxybutynin.

[0275] By acidic, aqueous processing of the extract from the polypropylene cylinder, it can be qualitatively demonstrated that oxybutynin is present in the organic diethyl ether phase, but not in the aqueous phase.

[0276] In this context, the microprocessing samples are also analyzed by HPLC analysis, which allows the following qualitative detection: Migration of oxybutynin into the packaging Affinity of migration into the polypropylene cylinder compared to the butyl rubber of the rubber parts Comparison with a blank material (not migrated) Exclusion of migration of impurity D into the polypropylene cylinder and the rubber parts Calculation of the maximum detectable concentration of oxybutynin in the samples

[0277] As previously stated, immediately after sterilization, 9.8% of the oxybutynin can no longer be recovered or detected in the oxybutynin-containing composition, whereby an average migration rate of 7.8% can be calculated across all packaging materials used.

[0278] At an oxybutynin concentration of 0.1%, 0.78 mg / syringe migrate into the packaging. With four packaging materials used, this corresponds to a mass of approximately 3.1 mg, which can be recovered during quantitative analysis (see Table 5). Table 5 : Calculation of the theoretically migrated amount of oxybutynin based on the remaining concentration in the solution after sterilization Concentration of the solution 0,1 % Volume of the solution 10 ml Oxybutynin / injection 10 mg average migration rate 7,84 % migrated amount / syringe 0.78 mg Amount in 4 syringes for quantitative detection 3.1 mg

[0279] The following samples are analyzed by HPLC: Rubber parts (aqueous, organic phase) Polypropylene cylinders (aqueous, organic phase) Blank Rubber parts (aqueous, organic phase) Blank Polypropylene cylinders (aqueous, organic phase)

[0280] Table 6 lists the amount of oxybutynin in the measured samples (no impurity D is found in each case). Table 6 : HPLC results of the extraction tests of the rubber parts and polypropylene cylinders Oxybutynin [µg / ml] further values Rubber part organic phase blank nb Rubber part organic phase 8,71 Rubber part aqueous phase blank nb Rubber part aqueous phase 2,71 Cylinder organic phase blank nb Cylinder organic phase 71,78 Cylinder aqueous phase blank nb Cylinder aqueous phase 13,39 Total rubber part 11,43 Total cylinders 85,17 Total packaging 96,59 Quantity / Rubber Part 2,86 Quantity / Cylinder 21,29 Quantity / syringe 24,15 Ratio of oxybutynin cylinder / oxybutynin rubber part (aqueous phase) 4,94 Ratio of Oxybutynin cylinder / Oxybutynin rubber part (organic phase) 8,24 Ratio of Oxybutynin cylinder / Oxybutynin rubber part (total) 7,45 Oxybutynin in HPLC sample 96,59 Sample dilution factor 10 Oxybutynin in extraction sample 965,92 µg Oxybutynin / injection 0.24 mg Migration rubber part 11,83 % Migration cylinder 88,17 % Migration aqueous cylinder 15,72 % Migration organic cylinder 84,28 %

[0281] Impurity D cannot be detected in either the aqueous or organic phase, indicating that the substance does not migrate into the cylinder or the rubber parts, as confirmed by thin-layer chromatography. This finding further confirms the assumption that hydrolysis of oxybutynin and subsequent migration of phenylcyclohexylhydroxyacetic acid (impurity D, or the hydrolysis product of oxybutynin) are not responsible for the decrease in oxybutynin concentration.

[0282] The comparison of the aqueous and organic samples from the microprocessing confirms the qualitative findings of the thin-layer chromatography, which show that oxybutynin is predominantly detected in the organic samples (84%). The value for the aqueous preparation of the cylinders is 13.4 µg / ml compared to the organic preparation of 71.8 µg / ml. This supports the statement that oxybutynin exists predominantly as a neutral amine base at pH 4 and is therefore soluble in diethyl ether (84%). The amounts of oxybutynin from the aqueous and organic samples are added to determine the total amount of oxybutynin after solid-phase extraction. 88% of oxybutynin migrates into the cylinder material, while only 12% migrates into the rubber parts.

[0283] Since the experiments were not conducted with exact amounts of solvent and without the use of an external standard, only 30% of the migrated oxybutynin was recovered. The low recovery rate can also be explained by a possibly incomplete solid-phase extraction with THF. The results of the HPLC measurements are within the range expected from the stability storage experiments. Table 6 shows that 965.92 µg were detected from four packaging materials after sample preparation, which corresponds to an amount of 0.24 mg per syringe.

[0284] Oxybutynin's solubility in aqueous media is limited, so the substance is used in aqueous systems in the form of its hydrochloride. Both the qualitative results of thin-layer chromatography and the quantitative values ​​of HPLC show that oxybutynin migrates into polypropylene after thermal stress. Oxybutynin migrates into the packaging material in its apolar form and can be detected again as the free amine base by extraction with THF.

[0285] Consequently, it is assumed that with increasing pH values ​​in the aqueous solution, oxybutynin is present in its free, uncomplexed form, which migrates into the packaging material. At reduced, strongly acidic pH values, oxybutynin is complexed by the hydrochloride and is then inhibited from migrating into polypropylene due to its polarity. Thus, the migration rate of oxybutynin after sterilization increases with increasing pH of the starting solution, and the migration rate decreases when the pH is lowered. Furthermore, with migration of the uncomplexed free amine base, a decrease in the pH in the solution after sterilization can be observed, since the hydrochloride is present as a free acid.

[0286] These assumptions are phenomenologically supported by a decrease in the oxybutynin concentration of 9.8% and a pH reduction of 0.19 (see Table 4). Effects of initial pH on oxybutynin loss

[0287] To verify the pH-dependent migration described above, the amount of HCl in the oxybutynin-containing composition (see Table 2) is adjusted to achieve pH values ​​of pH 3 and pH 5. To compensate for the oxybutynin loss after sterilization at pH 5, oxybutynin is used at a concentration of 105%. The solutions are sterilized in a polypropylene syringe, and specification parameters are determined after thermal application (see Table 7).

[0288] The following Table 7 shows the behavior of the specification parameters of oxybutyn-containing compositions in polypropylene plunger syringes for different initial pH values ​​(pH 3 or pH 5) after sterilization (compared to the initial values ​​before sterilization).

[0289] Table 7 shows that an initial pH of 3 leads to specifications-compliant results after sterilization and that the migration rate can be reduced from 9.8% (cf. Table 4) to 0%. Furthermore, after sterilization, the pH only drops by 0.04 (i.e., by 0.15 compared to the results at an initial pH of 3.92; cf. Table 4). These results also support the assumption that at lower pH values, oxybutynin is mainly present in its polar form and that migration in polypropylene can thus be surprisingly reduced, whereby the pH is also only slightly reduced after sterilization. After three months of storage under adverse conditions (40 / 75), a maximum migration rate of 0.3% and a stable pH of approximately 2.8 are observed.

[0290] Furthermore, it is shown that although increasing the initial pH to pH 5 results in an increased loss of oxybutynin (8%), this loss can surprisingly be compensated by increasing the oxybutynin concentration to 105%. After sterilization, specification-compliant values ​​of up to 95.9% oxybutynin and a pH of 3.8 can be achieved.

[0291] The experiments are repeated with other different initial pH values ​​(adjustment of the pH value by adjusting the HCl concentration). In this context, pH values ​​in the range of 2.86 to 5.2 are considered, and the dependence on the pH value drop after sterilization is documented (see Fig. 3This dependency can be represented by a nonlinear correlation, which can be described using a second-degree polynomial and a coefficient of determination of R 2< = 0.9799 (y = 0.2898x 2< - 1.7344x + 2.6217). Based on this function, further pH losses can now be interpolated and exemplary pH values ​​can be extrapolated. The graph shows a quadratic increase in pH value with increasing initial pH. From this, it can be deduced that for a pH specification of 3.5 to 4.2, a maximum initial pH value of 5.2 and a minimum initial pH value of 4.2 should be used.

[0292] In Fig. 4The dependence of oxybutynin loss after sterilization on the initial pH of the solution is visualized. Furthermore, it can be seen that the observed migration rate exhibits a linear trend in the pH range from 2.86 to 5.2. The derived linear correlation shows a coefficient of determination of R 2< = 0.8078 (y = 3.4196x - 8.1923) and illustrates that in the pH range from 3.8 to 4.2, an average oxybutynin loss of 5% can be expected after thermal application. Migration can be essentially suppressed at pH values ​​of 3 and increases to a migration loss of approximately 8% at pH values ​​above 5. Effect of oxybutynin concentration on other specification parameters

[0293] By adjusting the pH of the oxybutyn-containing composition to acidic conditions (pH of approximately 3) before sterilization, the specifications can be achieved by suppressing or reducing migration (see Fig. 4However, the physiological suitability of such acidic solutions (pH approx. 3) is sometimes not given. However, the loss of oxybutynin after sterilization within the specified pH range can surprisingly be compensated by using higher starting concentrations of oxybutynin.

[0294] Furthermore, the test series show that an increase in the initial pH value results in an increase in the migration rate (cf. Fig. 4). At an initial pH of 5, migration of 8% occurs, whereas very acidic solutions inhibit migration. In the pH range between 3.8 and 4.2, an average migration of 5.5% occurs. Using linear correlation, limit values ​​can be derived to define a possible overdose or overweight depending on the initial pH. Starting from a lower pH of 2.86, it is possible to keep the oxybutynin content within the specification (100% to 105% oxybutynin) up to a pH of 3.8 without overdosing. From a pH of 3.8, at least 5% overdosage can be used (limit threshold). In this case, an oxybutynin concentration of 105% to 110% can be used. Consequently, by adjusting the pH value, a specification-compliant oxybutynin content can be obtained after sterilization.

[0295] Further test series using 105% or 110% oxybutynin (see Table 8) show that specification conformity of the oxybutynin content can be achieved after sterilization, however the pH value lies outside the specified values ​​in the range of 3.8 to 4.2. Increasing the oxybutynin content to 105% without adjusting the amount of HCl results in an initial pH of the unsterilized solution of 3.63, which drops to 3.45 after sterilization. The migration of 4.6% can be compensated by overdosing. By increasing the oxybutynin content to 110% and adjusting the pH value by dosing HCl, a starting pH of 3.99 can be achieved. After sterilization, the oxybutynin content drops to 99.9%. At the same time, the pH drops to 3.6. Increasing the oxybutynin content to 115% while simultaneously adjusting the pH to 4.2 results in a migration rate of 6.6% and a drop in the pH to 3.7.

[0296] Table 8 below shows the behavior of the specification parameters of oxybutynin-containing compositions in polypropylene plunger syringes for different initial oxybutynin contents (at an initial pH of pH 3) after sterilization (compared to the initial values ​​before sterilization).

[0297] The experiments show that the percentage of surprisingly migrated oxybutynin can be compensated in an equally surprising way by higher starting concentrations, whereby the drop in pH is also a critical process parameter, which - equally surprisingly - can be controlled or compensated by a combination of pH adjustments and increasing the concentration of oxybutynin. Adjustment of pH and oxybutynin concentration

[0298] As previously stated, the migration of oxybutynin into the polypropylene packaging after sterilization can be surprisingly compensated by increasing the oxybutynin concentration, although this may not result in the pH limits being maintained (see Table 8).

[0299] As previously stated and in Fig. 3As shown, a surprising correlation was discovered between the initial pH of the oxybutynin-containing composition and the pH reduction after sterilization. At an initial pH of 4.5, a pH reduction of 0.75 occurs, resulting in a pH after sterilization of approximately 3.75. Consequently, a pH after sterilization of 3.7 can be achieved through a combination of increased oxybutynin concentration and adjustment of the initial pH. In particular, the initial pH before sterilization can be adjusted to 4.5 (especially at an oxybutynin concentration of 105%). This can also prevent pH values ​​that are sometimes out of specification, for example on an industrial scale, which is also associated with optimal process control.

[0300] Table 9 below shows the behavior of the specification parameters of oxybutynin-containing compositions in polypropylene plunger syringes for an initial oxybutynin content of 105% (at an initial pH of 4.5) after sterilization (compared to the initial values ​​before sterilization).

[0301] When using 105% oxybutynin at an initial pH of 4.5, there is a migration of 7.3%, and consequently both the oxybutynin content after sterilization and the pH are within the specifications. Influence of sterilization parameters

[0302] As previously described, the migration of oxybutynin into the polypropylene packaging material is primarily thermally induced. The average migration rate after thermal exposure through autoclaving is 5%. This correlation is also evident from the stability data of non-sterile formulations (see Table 3): migration of 2.6% occurs over a period of 3 months at 40 °C and 75% relative humidity.

[0303] To determine the influence of the selected sterilization parameters on the migration rate, two different sterilization programs (A and B) are tested and the relevant specification parameters are determined after thermal input (see Table 10).

[0304] Sterilization programs A and B differ in the thermal stress applied to the sample. The FO value serves as a measure for determining the thermal stress. This represents the equivalent stress of the sterilization program compared to sterilization at a reference temperature (121.1 °C) and is expressed in minutes. It serves to sum all lethal effects of a sterilization program (heating, sterilization, cooling) over the course of the program, thus enabling comparability. An FO value of 1 minute therefore corresponds to a thermal stress equivalent to 1 minute at 121.1 °C.

[0305] Sterilization program A achieves FO values ​​in the range of 19 to 23 min, with an effective sterilization holding time of at least 6 min at 121.5 °C. Sterilization program B additionally features an adaptation to comply with EP 5.1.1 (European Pharmacopoeia) with typical FO values ​​of 28 to 31 min and a sterilization holding time of at least 20 min at 121.5 °C.

[0306] The sterilization programs exhibit a significant difference in their plateau phase length (sterilization time), which corresponds to the thermal stress at < 121 °C. A higher loss of oxybutynin is expected after sterilization with program B.

[0307] Table 10 shows the reduction of pH and oxybutynin content in three different test series, whereby the three test series differ in the oxybutynin concentration (standard formulation or 105%) and the initial pH (3.9 to 4.5). Table 10: Comparison of specification parameters according to sterilization programs A and B Description Sterilization program pH Oxybutynin [%] Oxybutynin loss [%] Standard recipe unsterile 3,92 100,9 - Standard recipe A 3,73 91,1 9,8 Standard recipe B 3,68 94,1 6,8 Standard recipe unsterile 4,21 99,7 Standard recipe A 3,8 92,3 7,4 Standard recipe B 3,8 93,5 6,2 105% oxybutynin, pH 4.5 unsterile 4,5 104,2 - 105% oxybutynin, pH 4.5 A 3,8 97 7,2 105% oxybutynin, pH 4.5 B 3,7 96,9 7,3

[0308] The table shows that for all compositions with 105% oxybutynin and a pH of 4.5, specification-compliant values ​​were obtained. In this context, both sterilization programs enable effective sterilization, resulting in compositions that comply with specifications, as previously stated. Furthermore, no significant influence of the increased FO values ​​and the longer sterilization holding time on the reduction of the oxybutynin content can be observed. There are no significant differences between the two sterilization programs for either the pH value or the loss of oxybutynin (see Table 10). Only for the composition with an initial pH of 3.92 is there a slightly higher deviation in the oxybutynin loss (9.8%), which is even lower (6.8%) for the more demanding sterilization (sterilization program B), so that no conclusion can be drawn about increased product contamination.At an initial concentration of 105% and a pH of 4.5, the migration values ​​are 7.3% and 7.2%, respectively. From these results, it can be concluded that FO values ​​in the range of 19 to 31 min can be applied without significantly affecting the migration rate of oxybutynin or the pH loss. Summary of the previous results

[0309] The oxybutynin content in an aqueous 0.1% oxybutynin solution decreases after terminal steam sterilization in a polypropylene syringe. Furthermore, the pH of the solution decreases after thermal stress. Extraction tests on the polypropylene packaging used and subsequent qualitative analysis by thin-layer chromatography and quantitative analysis by HPLC demonstrate that the decrease in oxybutynin concentration is not, or not primarily, due to hydrolysis of the oxybutynin or the formation of an unknown impurity, but is due to migration of oxybutynin in an uncomplexed form (i.e., as the free amine base). This process is particularly thermally induced.

[0310] Furthermore, terminal steam sterilization with F0 values ​​in the range of 19 min to 31 min results in comparable migration rates of oxybutynin as well as pH losses, so that they can be used equally.

[0311] Furthermore, the migration of oxybutynin can be controlled by the pH of the solution before sterilization—lower pH values ​​lead to reduced migration. The migration rate at higher pH values ​​can be compensated by increasing the oxybutynin concentration in the solution before sterilization.

[0312] The relationship found between the initial pH value and the pH value after sterilization can be described with a second-order polynomial function. In combination with the overdosage, pH values ​​can be determined that lead to results that conform to specifications.

[0313] From the available tests, the pH and oxybutynin concentration ranges listed in Table 11 can be demonstrated (AE). The specification for the oxybutynin content of 95 to 105% is met in all combinations (AE). For combinations A and B at acidic pH values, the sterilized solution can be achieved with a pH specification starting at 2.8 (physiological aspects are not considered in this case). Combinations C and D are within the specification and have final pH values ​​of 3.5 to 4.2.

[0314] Combination E as an optimal combination is based on an overdose of oxybutynin of 105% and an initial pH value of 4.5, from which a final production-technically replicable pH value specification in the range of 3.5 to 4.2 is achieved.

[0315] The following Table 11 summarizes the pH and oxybutynin concentration corridors shown.

[0316] The surprising correlations summarized above were determined by the applicant within the framework of the aforementioned series of experiments. In this regard, the present invention has surprisingly succeeded in demonstrating an efficient concept for providing sterile oxybutyn-containing compositions, which, in particular, allows compositions with a defined active ingredient content and pH value to be obtained while simultaneously maintaining a low level of impurities. On this basis, an efficient and economical process can thus be provided. Experimental implementation Materials used Thin-layer chromatograms

[0317] Thin-layer chromatograms are performed on aluminum plates coated with silica gel 60 F254. Detection is performed with KMnO4 solution followed by heating on a hotplate. HPLC release analysis and stability tests

[0318] Device HPLC system (pump, autosampler, DAD detector, column oven) Detection 210 nm DAD spectrum (200-350 nm) Stationary phase C18 column (e.g. Kinetex) Length: 50 mm; inner diameter: 4.6 mm; particle size: 2.6 µm Mobile phase (gradient) Time / [min] Eluent A [%] Eluent B [%] 0,0 65 35 0,7 65 35 6,7 20 80 7,7 20 80 8,0 65 35 12,0 65 35 Column temperature 25 °C flow rate 1.3 ml / min Injection volume / 5 µl test solution for the content determination 40 µl test solution for impurity determination 40 µl calibration solution Duration / 12 minutes HPLC for evaluation of migration tests

[0319] Device Ultmate 3000 from thermo fisher scientific Column: Kinetex C18 Evo 150x4.6mm, 2.6µm Eluent A: 0.5% aqueous TFA solution Eluent B: Acetonitril Gradient: Time %B -5 22 0 22 0,7 22 6,7 78 10 78 Flow: 1 ml / min Detection: 215 nm Temperature: 30°C Duration: 10 minutes Injection volume: 20µl Packaging materials rubber sealing cap

[0320] Material: Bromobutyl rubber Silicone oil: Ph. Eur. 1,000 mPas Silicone quantity: 0.005 - 0.010 mg / cm 2< rubber stoppers

[0321] Material: Bromobutyl rubber Silicone oil: Ph. Eur. 1,000 mPas Silicone quantity: 0.040 - 0.080 mg / cm2 cylinder

[0322] Material: ExxonMobil PP 1013 H1 natural Silicone oil: Ph. Eur. "Dimeticone" 1,000 mPas Production of laboratory batches

[0323] Weigh 50% of the water directly into a suitable beaker. The sodium chloride and oxybutynin HCl are weighed into suitable glass containers. The components are then transferred to the beaker while stirring. The weighing containers are rinsed.

[0324] A large portion of the remaining water is then weighed into the beaker while stirring. The pH value is then measured and recorded. For formulations that require pH adjustment (3, 4.5, or 5), hydrochloric acid (0.001%) is added until the target pH is reached. The solution is then stirred for 30 minutes at 250 rpm using a magnetic stirrer.

[0325] The resulting solution is drawn manually into the PP syringe barrel, fitted with the rubber sealing cap and the filled syringe barrels are first blistered and then subjected to steam sterilization. Sterilization process

[0326] The SDR-12.12.60 / 2 large-capacity steam-air autoclave from SBM / Bosch is used for steam sterilization. However, for process optimization, only empty chamber runs are performed for these tests. The test syringes are moved to the center of the chamber on a pallet and autoclaved there without any filling load or the other pallets.

[0327] The blistered and boxed syringes are placed on an empty pallet in quantities of 5 to 25 boxes (depending on the test size) and equipped with probes for temperature measurement and program control.

[0328] All experiments whose results are discussed here are therefore not full-chamber experiments. Sterilization program A

[0329] Sterilization program A begins with a venting phase to reduce the air load in the blisters and folding boxes, alternating with steam bursts to slowly build pressure. Once these steps are completed, sterilization under support pressure for a minimum of 6 minutes at approximately 121°C follows. Finally, controlled, multi-stage cooling takes place while constantly maintaining the support pressure. After cooling, multi-stage drying takes place via the internal heat exchangers. This is achieved by means of venting and venting phases at temperatures between 60 and 70°C, so that a dry product can be removed after successful sterilization. On average, FO values ​​of 19 to 23 minutes are achieved. Sterilization program B

[0330] Sterilization program B is an extension of sterilization program A in that it ensures a sterilization time of at least 20 minutes at approximately 121 °C. The remaining phases of the program are equivalent to sterilization program A. The extended plateau phase during sterilization results in F0 values ​​in the range of 28 minutes to 31 minutes, which corresponds to an increase in the sterilization load of approximately 50% to 60%. stability

[0331] After sterilization, the test batches are stored in stability chambers at 25 °C / 60% RH and 40 °C / 75% RH for up to 3 months. Extraction tests

[0332] The 0.1% oxybutynin solution, as described in Table 2, is prepared on a laboratory scale as described in the "Preparation of Laboratory Batches" section, and the filled syringes are steam sterilized. The syringes are then stored for 10 days at both 25°C / 60% RH and 40°C / 75% RH.

[0333] Four of the obtained, stored samples are subjected to extraction tests together with untreated reference packaging (blank). The contents of oxybutynin solution from four filled syringes are discarded, and the cylinders and rubber parts are rinsed with distilled water. The plunger rods of all four syringes are unscrewed and discarded. The rubber sealing caps and rubber stoppers are removed and separated from the PP cylinder material. The empty syringe bodies and rubber parts are crushed into uniform pieces (average PP cylinder size: 1 cm², average GT size: 9 mm²).

[0334] The four crushed syringes and the crushed rubber pieces are separately heated to reflux with 150 ml of THF for 1.5 h. After 1.5 h, the mixtures are cooled to room temperature, and the packing material is filtered off and rinsed with approximately 30 ml of THF. The filtrate is evaporated to dryness.

[0335] The filtrate from the rubber parts is a yellowish oil (1.993 g). The filtrate from the cylinders is a violet oil (0.1951 g). Qualitative detection with DC

[0336] The resulting extracts of rubber parts and cylinders, as well as the reference substances of oxybutynin hydrochloride and impurity D, are dissolved in acetone. Cyclohexane / ethyl acetate 1:6 is used as the mobile phase. Acid-aqueous microprocessing of the extracts

[0337] The extracts from the rubber parts and the cylinder are subjected to a non-volumetric microprocessing. The dry extract is dissolved in approximately 3 ml of buffer solution (pH 4, citric acid, sodium hydroxide, hydrochloric acid) and 3 ml of diethyl ether and shaken out. The organic phase is removed. Both phases are filtered through a PTFE syringe filter. Quantitative detection with HPLC Sample preparation for HPLC

[0338] The aqueous and organic samples from the cylinder and rubber parts are evaporated to dryness in a stream of argon. The residue is dissolved in 1 ml of THF (tetrahydrofuran) and quantitatively transferred to a 10 ml volumetric flask with another ml. The flask is then made up to volume with 0.1% TFA water. The resulting turbidity is removed using a PTFE syringe filter.

Claims

1. Process for preparing a sterile oxybutynin-containing composition in a preferably ready-to-use piston syringe, in particular a disposable piston syringe, and / or for preparing a preferably ready-to-use, sterile piston syringe filled with an oxybutynin-containing composition, in particular a disposable piston syringe, wherein the plunger syringe has a syringe body on the one hand and a syringe plunger with a plunger stopper on the other hand, wherein the syringe body is formed from a polypropylene, and wherein the final oxybutynin-containing composition obtained after completion of the process, in particular after process step b), is in the form of a sterile aqueous composition, in particular a terminally sterilized composition, and has the following specification requirements (i) and (ii) and / or (iii), preferably (i), (ii) and (iii): (i) a predetermined specification concentration of oxybutynin, preferably in the form of the hydrochloride, with a predetermined deviation of at most ± 5% with respect to the concentration of oxybutynin, (ii) a predetermined specification pH value with a predetermined deviation of at most ± 0.5 pH units, (iii) a predetermined specification maximum amount of oxybutynin degradation product(s), in particular reactively produced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively produced oxybutynin degradation product(s), preferably phenylcyclohexyl hydroxyacetic acid; wherein the method comprises the following steps: a) providing an oxybutynin-containing starting composition in the piston syringe and / or filling the piston syringe with an oxybutynin-containing starting composition and subsequently b) heat sterilization, in particular steam sterilization, preferably water-steam sterilization, preferably terminal sterilization, of the oxybutynin-containing starting composition in the plunger syringe and / or the plunger syringe filled with the oxybutynin-containing starting composition to obtain the sterile oxybutynin-containing final composition in the preferably ready-to-use plunger syringe and / or to obtain the preferably ready-to-use, sterile plunger syringe filled with the oxybutynin-containing composition, wherein the migration and / or incorporation of the oxybutynin into the syringe barrel and / or into the plunger stopper occurring in the process, in particular in process step b), and / or the degradation of the oxybutynin occurring in the process, in particular in process step b), in particular the reactive degradation of the oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation, preferably the degradation to phenylcyclohexylhydroxyacetic acid, is controlled and / or compensated for in such a way and with the proviso that the sterile oxybutynin-containing final composition obtained after carrying out process step b) fulfills the above-mentioned specification requirements (i) and (ii) and / or (iii), preferably (i), (ii) and (iii), and the sterile oxybutynin-containing final composition is obtained in the preferably ready-to-use plunger syringe or the preferably ready-to-use sterile plunger syringe filled with the oxybutynin-containing final composition, wherein the migration and / or incorporation of the oxybutynin into the syringe barrel and / or into the plunger stopper occurring in the process, in particular in process step b), and / or the degradation occurring in the process, in particular in process step b), in particular the reactive degradation of the oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation of the oxybutynin, preferably the degradation to phenylcyclohexylhydroxyacetic acid, is controlled and / or monitored, in particular prevented and / or minimized and / or compensated, by at least one of the following measures and / or steps (1), (2), (3) and / or (4): (1) adjustment and / or use of an increased concentration and / or amount of oxybutynine, preferably in the form of the hydrochloride, in the starting composition compared to the specification concentration and / or specification amount of the oxybuty-nine, preferably in the form of the hydrochloride; (2) adjustment of a pH value in the starting composition which differs from the specification pH value, in particular an increased pH value; (3) adjustment and / or selection of the sterilization conditions, in particular selected from the group of sterilization type, sterilization duration, sterilization temperature, sterilization pressure, sterilization atmosphere and combinations thereof, preferably adjustment and / or selection of the F0 value of the sterilization; (4) equipping and / or treating, in particular coating, the syringe barrel, preferably the inner wall of the syringe barrel, and / or the plunger stopper with at least one migration- and / or degradation-reducing agent.

2. Method according to claim 1, wherein at least measure and / or step (1), optionally in combination with measure and / or step (2), (3) and / or (4), is carried out; and / or wherein at least measure and / or step (1) and measure and / or step (2), optionally in combination with measure and / or step (3) and / or (4), are carried out; and / or wherein at least measure and / or step (1) and measure and / or step (2) and measure and / or step (3), optionally in combination with measure and / or step and / or step (4), are carried out.

3. Process according to claim 1 or 2, wherein, in the case of measure and / or step (1), in the starting composition the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, is adjusted by 1 % to 20 % above the specification concentration and / or specification amount of oxybutynin, preferably in the form of the hydrochloride, of the final composition; and / or wherein, in the case of measure and / or step (1), in the starting composition the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, is adjusted to a value in the range of 101 % to 120 % of the specification concentration and / or specification amount of oxybutynin, preferably in the form of the hydrochloride, of the final composition; and / or wherein, in the case of measure and / or step (1), the concentration and / or amount of oxybutynin, preferably in the form of the hydrochloride, in the starting composition is adjusted to a value in the range from 0.51 mg / ml to 3.5 mg / ml.

4. Process according to any preceding claim, wherein, in the case of measure and / or step (2), the pH of the starting composition is adjusted by 0.02 pH units to 2.4 pH units above the specification pH of the final composition; and / or wherein, in the case of measure and / or step (2), the pH of the starting composition is adjusted from 5 % to 90 % above the specification pH of the final composition; and / or wherein, in the case of measure and / or step (2), the pH of the starting composition is adjusted to a value in the range from 2.8 to 7.5; and / or wherein, in the case of measure and / or step (2), the pH of the starting composition is adjusted using and / or by means of hydrochloric acid.

5. Process according to one of the preceding claims, wherein, in the case of measure and / or step (3), the heat sterilization, in particular steam sterilization, preferably steam sterilization, preferably thermal sterilization, is carried out with an F0 value in the range from 6 min to 45 min; and / or wherein, in the case of measure and / or step (3), the sterilization conditions are set to an F0 value in the range from 6 min to 45 min; and / or wherein, in the case of measure and / or step (4), the finishing and / or treatment, in particular coating, of the syringe barrel, preferably of the inner wall of the syringe barrel, and / or of the plunger stopper is carried out with a silica-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate, in particular by means of siliconization or silicatization; and / or wherein, in the case of measure and / or step (4), the migration- and / or degradation-reducing agent is a silicon-containing, in particular silicone- or silicate-based agent, preferably silicone oil or silicate.

6. Process according to one of the preceding claims, wherein the migration and / or incorporation of the oxybutynin into the syringe barrel and / or into the plunger stopper occurring in the process, in particular in process step b), and / or the degradation occurring in the process, in particular in process step b), in particular the reactive degradation of the oxybutynin, preferably the hydrolytically and / or oxidatively induced degradation of the oxybutynin, preferably the degradation to phenylcyclohexyl hydroxyacetic acid, by adjusting the ratio of (i) oxybutynin in the form of the free base, in particular oxybutynin in the form of the free amine base, on the one hand, and (ii) oxybutynin in the form of the complexed and / or coordinated and / or salified and / or protonated base, in particular oxybutynin in the form of the complexed and / or coordinated and / or salified and / or protonated amine base, preferably oxybutynin in the form of the hydrochloride, on the other hand, in particular wherein the ratio is controlled, in particular prevented and / or minimized in the direction of (ii) oxybutynin in the form of the complexed and / or coordinated and / or salified and / or protonated base, in particular oxybutynin in the form of the complexed and / or coordinated and / or salified and / or protonated amine base, preferably oxybutynin in the form of the hydrochloride, is displaced, preferably by adjustment, in particular lowering and / or reducing, the pH value and / or by adjusting an in particular low pH value, in particular to a pH value in the range from 2.8 to 5, preferably in the range from 3.1 to 4.5, preferably in the range from 3.2 to 4.2, in the starting composition and / or by adding an acid to the starting composition.

7. Process according to one of the preceding claims, wherein the plunger syringe filled with the oxybutynin-containing composition has been placed in a water- and / or germ-tightly sealed package before carrying out the heat sterilization, preferably steam sterilization, preferably terminal sterilization, wherein at least a part of the package is designed to be at least permeable to water vapour, in particular wherein the package is likewise sterilized when the steam sterilization is carried out.

8. Process according to one of the preceding claims, wherein the final oxybutynin-containing composition obtained after completion of the process, in particular after process step b), is in the form of a sterile aqueous composition, in particular a terminally sterilized composition, and has the following specification requirements (i) and (ii) and / or (iii), preferably (i), (ii) and (iii): (i) a predetermined specification concentration of oxybutynin, preferably in the form of the hydrochloride: 0.5 mg / ml to 2 mg / ml with a maximum deviation of ± 5%, based on the concentration of oxybutynin, preferably 1 mg / ml with a maximum deviation of ± 0.05 mg / ml, 8. process according to one of the preceding claims, (ii) a predetermined specification pH value: 2.8 to 5.2, in particular 3 to 5, preferably 3.2 to 4.8, preferably 3.5 to 4.5, particularly preferably 3.5 to 4.2, very particularly preferably 3.8 to 4.2, (iii) a predetermined specification amount of oxybutynin degradation product(s), in particular reactively produced oxybutynin degradation product(s), preferably hydrolytically and / or oxidatively produced oxybutynin degradation product(s), preferably phenylcyclohexyl hydroxyacetic acid: at most 0.5 % by weight, in particular at most 0.2 % by weight, based on the total amount of oxybutynin used, preferably oxybutynin hydrochloride.